Nothing Special   »   [go: up one dir, main page]

EP0335669A2 - Hydrophilic foam compositions - Google Patents

Hydrophilic foam compositions Download PDF

Info

Publication number
EP0335669A2
EP0335669A2 EP89303064A EP89303064A EP0335669A2 EP 0335669 A2 EP0335669 A2 EP 0335669A2 EP 89303064 A EP89303064 A EP 89303064A EP 89303064 A EP89303064 A EP 89303064A EP 0335669 A2 EP0335669 A2 EP 0335669A2
Authority
EP
European Patent Office
Prior art keywords
hydrophilic
adjuvant
foam composition
water
prepolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP89303064A
Other languages
German (de)
French (fr)
Other versions
EP0335669A3 (en
EP0335669B1 (en
Inventor
Robert W. Sessions
Roy D. Carr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferris Manufacturing Co
Original Assignee
Ferris Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22638574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0335669(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferris Manufacturing Co filed Critical Ferris Manufacturing Co
Priority to AT89303064T priority Critical patent/ATE91074T1/en
Publication of EP0335669A2 publication Critical patent/EP0335669A2/en
Publication of EP0335669A3 publication Critical patent/EP0335669A3/en
Application granted granted Critical
Publication of EP0335669B1 publication Critical patent/EP0335669B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208Tissues; Wipes; Patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/046Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/26Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/425Porous materials, e.g. foams or sponges
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/44Medicaments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0019Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00Polymeric products of isocyanates or isothiocyanates
    • C08G18/06Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08Processes
    • C08G18/10Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00361Plasters
    • A61F2013/00365Plasters use
    • A61F2013/00463Plasters use haemostatic
    • A61F2013/00472Plasters use haemostatic with chemical means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/15Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/53Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
    • A61F2013/530481Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having superabsorbent materials, i.e. highly absorbent polymer gel materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/15Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/53Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
    • A61F2013/530802Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium characterized by the foam or sponge other than superabsorbent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2101/00Manufacture of cellular products
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2110/00Foam properties
    • C08G2110/0041Foam properties having specified density
    • C08G2110/0066≥ 150kg/m3
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2110/00Foam properties
    • C08G2110/0083Foam properties prepared using water as the sole blowing agent

Definitions

  • the present invention relates to novel foam products and, more particularly, to highly absorbent hydrophilic polyurethane foam compositions which have liquid release and exchange characteristics.
  • Absorbent pads such as for use in contact with the skin for absorbing body fluids, are well known. Such pads are useful for numerous applications, including for example as a diaper, sanitary napkin, bandage, wound dressing or the like.
  • Absorbent pads have been made of a wide variety of materials. For example, such pads have been made using graft copolymers, as described in U.S. 4,055,184.
  • the absorbent pad therein described includes an absorbent mass comprising a solid finely-­divided mixture of a completely hydrolyzed starch-­polyacrylonitrile graft copolymer and a non-­irritating and non-toxic water-soluble basic material such as, for example, sodium bicarbonate which may be admixed with and distributed in a highly porous web or batt of cotton linters, layers of creped tissue or a mass of shredded polyurethane foam particles.
  • Pads in the form of a foam and which have been made from various superabsorbent materials are likewise known.
  • U.S. 4,394,930 discloses an absorbent foam product prepared by mixing together a solid, particulate, water-­insoluble, water-swellable polymer such as "hydrogels", “hydrocolloids” or “superabsorbents” which are lightly cross-linked polymers containing a plurality of hydrophilic groups, such as carboxyl, carboxamide, sulfonate salt or hydroxyl groups, a blowing agent, and a liquid polyhydroxy organic compound and allowing the mixture to foam.
  • hydrophilic groups such as carboxyl, carboxamide, sulfonate salt or hydroxyl groups
  • Polyurethane foams treated and/or prepared in a manner so as to render them hydrophilic are also known.
  • U.S. 3,586,648 discloses a hydrophilic polyurethane foam prepared by the so-­called “one-shot” technique and is stated to include a carboxymethyl cellulose or a carboxymethyl cellulose salt.
  • U.S. 4,497,914 discloses an ostomy gasket composition derived from the non-aqueous reaction of a polyisocyanate and a polyoxyalkylene polyol.
  • a hydrophilic filler such as hydroxyethylcellulose, hydroxypropylcellulose or mixtures thereof, are incorporated into the polyol phase prior to reaction.
  • Hydrophilic cross-linked polyurethane foams are disclosed in U.S. 3,903,232. Such foams are prepared by reacting particular isocyanate-capped polyoxyethylene polyols having an isocyanate functionality greater than two with large amounts of an aqueous reactant, preferably water.
  • the foam is said to be useful for the absorption of body fluids and may be used for external body cleaning, for internal body usage, such as is necessary in dental and medical applications, and as intimate absorptive products such as diapers, sanitary napkins, catamenial devices and the like.
  • adsorbent pads using hydrophilic foam include U.S. 3,961,629, which discloses a hydrophilic polyurethane foam in which the foam pores have a surfactant coating to accelerate absorption of body fluids into the pores at medically acceptable rates.
  • the foam is rendered hydrophilic by coating the pore walls with a thin layer of a surfactant.
  • Hygroscopic agents such as glycerine as well as other agents, such as germicidal and therapeutic agents, may be incorporated into the foam.
  • U.S. 4,664,662 discloses an absorbent wound dressing which comprises an absorbent foam material retained in a water permeable, porous bag.
  • the absorbent foam is preferably a hydrophilic polyurethane foam which can be made from HYPOL isocyanate-capped polyether prepolymer marketed by W.R. Grace and Co. and non-ionic surfactants.
  • Physiologically active components such as local anaesthetics, antibacterial agents, antifungal agents and the like which are compatible with the absorbent material may be incorporated into the wound dressing.
  • Hydrophilic polyurethane foam compositions are also disclosed in U.S. 4,339,550.
  • the hydrophilic foam composition is prepared by the "in situ” reaction of an isocyanate-capped polyether prepolymer having a functionality of from about 2 to about 8, water, and a chemically compatible, essentially non-­polar, volatile organic compound.
  • the foam is stated to be capable of achieving a sustained, controlled release of the volatile materials from the foam structure.
  • Suitable "control release" ingredients for use in controlling the rate of release of the volatile ingredients include polyols, such as propylene glycol and glycerin, and materials classified as gums.
  • a principal object of the present invention to provide a polyurethane foam composition which is hydrophilic, highly absorbent and which releasably carries an adjuvant which is capable of being released from the foam in the presence of an external liquid which is preferentially absorbed by the foam composition.
  • a more detailed object of the present invention is to provide a foam composition which is capable of releasing an adjuvant to a designated situs and which is capable of absorbing external liquids from that situs.
  • a related object is to provide such a polyurethane foam composition which will tightly hold the external fluid once it is absorbed.
  • Another object of the invention is to provide a hydrophilic foam composition that can be prepared at ambient temperature.
  • a further object of the present invention is to provide a composite for use in a wound dressing which includes a hydrophilic foam composition as described herein. Another object is to provide a method for making such a composite.
  • the present invention is predicated on the discovery that a highly absorbent hydrophilic polyurethane foam composition which releasably carries an adjuvant and is capable of releasing at least a portion of the adjuvant while preferentially absorbing external liquid upon exposure of the foam composition to the external liquid, can be made by incorporating a hydrophilic agent and a releasably carried adjuvant in the foam composition. Incorporation of the adjuvant in the resulting foam is achieved by the in situ reaction of a hydrophilic isocyanate-capped polyether prepolymer, a hydrophilic agent, water, adjuvant and a wetting agent.
  • the present invention provides a hydrophilic polyurethane foam composition
  • a hydrophilic polyurethane foam composition comprising the in situ reaction product of an isocyanate-capped polyether prepolymer, a hydrophilic agent capable of absorbing water, an adjuvant comprising a mono or polyhydric alcohol, a wetting agent for enhancing the wettability of the foam composition, and water.
  • the hydrophilic foam is capable of exchanging an external fluid and tightly carrying the external fluid in preference to at least a portion of the adjuvant so that upon exposure of the hydrophilic foam composition to an external fluid, such as, for example, to the exudate of a wound, the composition will absorb the external fluid and tightly carry it in preference to at least a portion of the adjuvant so that at least a portion of the adjuvant is released from the foam.
  • the present invention provides a novel wound dressing which incorporates the novel hydrophilic polyurethane foam.
  • the present invention provides a method of treating a wound which includes applying to the wound the novel hydrophilic foam composition disclosed herein or a wound dressing made therefrom.
  • composites which include the hydrophilic foam composition described herein and a method for making such composites are provided.
  • a highly absorbent hydrophilic polyurethane foam composition which includes a releasably carried adjuvant which is capable of being emitted from the composition in the presence of an external liquid.
  • the foam composition of this invention is the in situ reaction product of a reactant composition comprising an isocyanate-capped polyether prepolymer, a hydrophilic agent, an adjuvant, water and a surfactant or wetting agent.
  • the hydrophilic foam composition when applied to a moisture laden surface will preferentially absorb moisture from that surface while releasing the adjuvant carried by the composition.
  • the hydrophilic polyurethane foam composition of the present invention is particularly useful as the absorbent pad of an occlusive or semi-­occlusive wound dressing, commonly applied to injuries such as abrasions, incisions, punctures, lacerations, ulcers, sores, burns and the like to aid in stopping bleeding and in protecting the wound from contamination.
  • the foam composition of the present invention When applied to a wound, the foam composition of the present invention will absorb and retain a high volume of aqueous fluid, i.e., wound exudate, and will release the adjuvant to the wound situs.
  • a wound dressing which incorporates the foam composition of the present invention may be prepared which is advantageously capable of providing enhanced hemostatic and chemical debridement characteristics as well as transdermal, bacteriostatic, emollifying, demulcifying and wound cleansing characteristics.
  • the foam composition absorbs exudate moisture from the wound.
  • the foam In absorbing the exudate moisture, the foam swells to conform to the wound contour so as to become thermally insulative to the surface of application, while at the same time holding moisture against the surface in order to keep that surface moist.
  • the foam composition will then assist in maintaining a warm, moist and sealed wound with appropriate pH to promote epidermal resurfacing and re-epithelization.
  • a wound dressing which includes the foam composition of the present invention does not adhere to the wound and thus does not cause reinjury upon its removal from the wound. This is believed to be due to the liquid exchange and the maintenance of a moist environment about the wound.
  • the hydrophilic polyurethane foam compositions of the present invention are prepared using an isocyanate-capped polyether prepolymer.
  • these prepolymers must be safe for use in the human body, and are preferably capable of foaming in an aqueous system in the absence of a catalyst. On the other hand, such prepolymers should not dissolve in the aqueous liquid.
  • it is highly desirable that these prepolymers cure to form a porous cellular foam matrix to enable both absorption of external fluids and carriage of the chosen adjuvant in the foam composition.
  • the formation of a cellular foam matrix is preferred due to a large volume available not only for absorption but the containment of the chosen adjuvant. It is further desirable that the prepolymers are capable of curing in the presence of water, in the absence of catalyst, and at ambient temperature.
  • Isocyanate-capped polyether prepolymers such as those disclosed in U.S. Patent Nos. 3,903,232 and 4,137,200 are suitable for use in the present invention. These prepolymers have a defined average isocyanate functionality greater than 2. These prepolymers may be capped with aromatic isocyanates, such as, for example, toluene diisocyanate or methylene diphenyl isocyanate, or with aliphatic isocyanates, such as isophorone diisocyanate.
  • Isocyanate-capped polyether prepolymers which have been found suitable for use in the practice of the present invention include prepolymers sold under the trademark HYPOL. Examples include HYPOL FHP 2000, HYPOL FHP 2002, HYPOL FHP 3000, HYPOL FHP 4000, HYPOL FHP 5000, HYPOL X6100 and HYPOL hydrogel.
  • HYPOL 2000, HYPOL 2002 and HYPOL 3000 prepolymers are derived from toluene diisocyanate.
  • FHP 2000 and FHP 2002 both have an equivalent weight (per NCO) of 625, an NCO content of 1.60 meq/g and a specific gravity of 1.19.
  • the viscosity of FHP 2000 is 18,500 cps (Brookfield LVF, #4 Spindle, 12 rpm at 25°C) and that of FHP 2002 is 20,000.
  • FHP 3000 has an equivalent weight (per NCO) of 425, an NCO content of 2.35 meq/g, a specific gravity of 1.15 and a viscosity (measured as described above) of 10,500.
  • HYPOL hydrogel is likewise derived from toluene diisocyanate. It has an NCO content of 0.5-0.9 meq/g and a viscosity of 10,000 to 12,000 cps at 25°C.
  • AQUAPOL prepolymer suitable for use in the present invention and derived from toluene diisocyanate
  • AQUAPOL prepolymer commercially available from Freeman Chemical Corporation.
  • AQUAPOL prepolymers have an NCO-value of 2.5 to 3.0 and are formed from the reaction of toluene diisocyanate and an organic polyether polyol containing at least 40 percent by weight ethylene oxide adducts as described at Col. 2, lines 3-22 of U.S. 4,517,326.
  • TREPOL isocyanate-capped prepolymer suitable for use in the present invention and which is derived from toluene diisocyanate
  • TREPOL prepolymers have an -NCO content of 1.4 milliequivalents per gram and a viscosity at 90°C of 4,700 cps.
  • the HYPOL FHP 4000 and HYPOL FHP 5000 prepolymers are derived from methylene diisocyanate.
  • FHP 4000 has an equivalent weight (per NCO) of 476, an NCO content of 2.10 meq/g, a Brookfield viscosity (LVF, #4 Spindle, 12 r.p.m. at 25°C) of 20,000 and specific gravity of 1.17.
  • FHP 5000 has an equivalent weight (per NCO) of 392, an NCO content of 2.55 meq/g, a Brookfield viscosity (measured as for FHP 4000) of 18,000 and a specific gravity of 1.17.
  • An example of an isocyanate-capped prepolymer suitable for use in the present invention and derived from isophorone diisocyanate is HYPOL X6100. It has an -NCO content of 1.8 meq/grams and a viscosity at 25°C of 12,000 cps.
  • the amount of prepolymer in the reactant composition used to prepare the hydrophilic foam composition is not particularly critical, but depends on a number of factors, including the proportion of other components in the reactant composition as will be described in greater detail hereinafter. However, there should be sufficient prepolymer to form a polyurethane foam, to releasably contain the adjuvant and to adequately contain the hydrophilic agent. To that end, the ratio of prepolymer to hydrophilic agent should be such that the reactant composition does not degrade or break up into its separate constituents. Furthermore, while there should be sufficient prepolymer to provide integrity to the foam matrix, there should not be so much prepolymer that the resulting polyurethane composition becomes unworkable. In short, and particularly where the final composition is to be applied to the skin, the resulting foam composition is desirably relatively smooth and soft while exhibiting the desired absorbence characteristics so that it does not irritate or otherwise harm the skin.
  • the concentration of prepolymer further depends on its isocyanate functionality and the degree of crosslinking desired in the final foam composition. In general, the greater the isocyanate functionality, the greater the degree of cross-linking in the cured foam matrix.
  • the reactant composition will comprise from about 20% to about 60% by weight prepolymer.
  • the reactant composition will comprise from about 45% to about 50% by weight of the prepolymer.
  • the prepolymers may be used alone or in combination.
  • the reactant composition further includes a hydrophilic agent which is incorporated into the foam composition to absorb external liquid, such as wound exudate, and to retain such liquid in the composition.
  • a hydrophilic agent which is incorporated into the foam composition to absorb external liquid, such as wound exudate, and to retain such liquid in the composition.
  • the hydrophilic agent When applied to a wound, the hydrophilic agent is believed to work in conjunction with the foam matrix to hold moisture at the surface of the wound. This allows healing agents exuded by the wound to be concentrated and held at the wound surface.
  • the hydrophilic agent incorporated into the composition is believed to absorb fluid from the wound to assist thickening of the blood, i.e., it serves as a hemostat.
  • the absorption of exudate by the hydrophilic agent, and the subsequent swelling of the agent results in the removal of inflammatory exudates and particles that would otherwise hinder tissue repair or cause eschar formation. Necrotic debris and bacteria are likewise removed as autolysis, i.e. chemical debrid
  • the hydrophilic agent is preferably a highly absorbent polymer, commonly known as a superabsorbent polymer.
  • a highly absorbent polymer commonly known as a superabsorbent polymer.
  • One measure of polymer absorbency is its fluid uptake capability, well known by those skilled in the art.
  • Hydrophilic agents suitable for use in the present invention include polymers that are capable of absorbing at least 50 times their weight of water, that is, such agents have a fluid uptake of at least 50 ml/g. Hydrophilic agents having an even higher fluid uptake, such as of at least about 100 ml/g and even higher, that is, at least about 150 ml/g are preferred.
  • Suitable superabsorbent polymers include sodium and aluminum salts of starch grafted copolymers of acrylates and acrylamides and combinations thereof, as well as polyacrylate salts.
  • the resulting foam composition desirably has the ability to hold at least about 3 times its weight in liquid. In the preferred embodiment, the resulting foam composition will have the ability to tightly hold at least about 3 times its weight in fluid.
  • tightly hold or “tightly bound” liquid means the relative amount of liquid retained by the sample after compression, as described in detail hereinafter.
  • Hydrophilic polymers which have been found suitable for use in the foam composition of this invention are commercially available from Grain Processing Corporation. These polymers include a starch-g-poly(2-propenamide-co-2-propenoic acid, mixed sodium and aluminum salt) sold under the trademark WATER LOCK A-222; a starch-graft copolymer of polyacrylic acid and polyacrylamide having the chemical name starch-g-poly(2-propenamide-co-2-­propenoic acid, sodium salt), sold under the trademark WATER LOCK A-100; a starch g-poly(2-­propenamide-co-2-propenoic acid, sodium salt), sold under the trademark WATER LOCK A-200.
  • Superabsorbent polymers commercially available from Grain Processing Corporation under the trademark WATER LOCK D-212 and WATER LOCK D-242 are likewise suitable. These polymers have the chemical name starch-g-poly(2-­propenamide-co-2-propenoic acid, mixed sodium and aluminum salt).
  • the superabsorbent polymer commercially available under the trademark WATER LOCK G-400 is also suitable for use in the making of the hydrophilic foam composition of the present invention.
  • This superabsorbent polymer may be chemically identified as a poly(2-propenamide-co-2-­propenoic acid, sodium salt).
  • Other super absorbent powders suitable for use in the present invention are sold by Grain Processing Corporation under the trademark WATER LOCK B, C, and H.
  • a suitable superabsorbent polymer is poly-2-propenoic acid, sodium salt, sold under the trademark AQUA KEEP J-500 supplied by Sanyo Corp.
  • super absorbent polymers sold by Arakawa Chemical (USA) Inc. under the trademark ARASORB are suitable.
  • the preferred hydrophilic polymers are WATER LOCK A-100, A-200, A-222 and AQUA KEEP J-500.
  • the hydrophilic polymers may be used alone, or in combination to achieve the desired absorptivity characteristics in the foam composition.
  • the hydrophilic agent may comprise additives in addition to the superabsorbent polymers, provided, as discussed above, the additives do not reduce the fluid uptake of the hydrophilic agent to below about 50 ml water per gram of hydrophilic agent and the fluid uptake of the final foam composition is not less than about 3 times its weight.
  • additives include methylcellulose, guar gum, pectin, karaya gum, chitosan, agar, acacia powder, carrageenan, gelatin and combinations thereof.
  • the amount of hydrophilic agent used and the type of it, in terms of its fluid uptake, that may be satisfactorily used to make the foam composition is not critical, but is, instead, dependent on the intended application of the composition. Stated another way, the greater the quantity of external liquid to be absorbed, e.g., the greater the amount of wound exudate, the greater the amount of hydrophilic agent that should be employed. In the alternative, the greater the amount of wound exudate to be absorbed, the greater the fluid uptake of the hydrophilic agent used, should be. For example, for an ulcerated wound where there is a high volume of wound exudate, a hydrophilic agent with high uptake is desirable. In addition, it may well be determined that the amount of hydrophilic agent may need to be increased.
  • the foam when it is to be applied to a small cut or light burn it may be suitable to use less hydrophilic agent or to use a hydrophilic agent with a lower fluid uptake. Determination of the type and amount of hydrophilic agent used is well within the ability of one skilled in the art in light of the disclosure herein.
  • the amount of hydrophilic agent should not be so great as to undesirably reduce the strength of the foam composition or result in a loss of polymer from the foam, although some loss of hydrophilic agent may be tolerated without adversely affecting the ability of the foam to absorb external liquid.
  • the amount of hydrophilic agent employed in the reactant composition will also depend on the absorbency of the material used. As previously indicated, it is preferable that a sufficient amount of hydrophilic agent be employed so that the resulting foam composition is capable of absorbing at least about 3 times its weight in external liquid. Typically this can be achieved by including from about 5 wt.% to about 20 wt.% hydrophilic agent in the reactant composition.
  • the reactant composition of this invention further includes an adjuvant; preferably, a water-­soluble adjuvant.
  • the adjuvant is releasably carried by the resulting foam composition for subsequent release to a chosen situs of application. Release of the adjuvant occurs in the presence of an external liquid, such as wound exudate, which is preferentially absorbed by the foam composition. Absorption of the external liquid causes at least a portion of the adjuvant to be released.
  • the adjuvant Prior to curing, the adjuvant serves as a plasticizer for the reactant composition. It extends the curing time of the composition thereby allowing it to be more thoroughly mixed and formed. Once cured, the foam composition is softened by the adjuvant, allowing the foam to be more pliable and more easily applied to the skin surface or other surface of choice. Additionally, the adjuvant may be somewhat hygroscopic lending further to the hydrophilic nature of the foam composition.
  • Adjuvants suitable for use in the foam composition of the present invention are mono, di and polyhydric alcohols.
  • the adjuvants are water soluble so that they may be readily released from the composition upon contact of the foam composition with an external liquid.
  • the adjuvant be capable of contacting skin without adverse side effects.
  • the adjuvant comprise a chemical compound that will have the ability to open the skin pores to achieve a demulcent effect to relieve pain and/or irritation and to achieve an emollient effect to soften the skin and prevent maceration.
  • the adjuvant be compatible with therapeutic or other agents which may be carried by the adiuvant for subsequent delivery to the situs of application.
  • Suitable adjuvants include water soluble alcohols, including monols, diols and polyhydric alcohols.
  • monols include ethyl alcohol and isopropyl alcohol.
  • suitable diols are propylene glycol, polyethylene glycol and polypropylene glycol.
  • suitable polyhydric alcohols are glycerin, 1,2,4-­butanetriol, trimethylolpropane, pentaerythritol and sorbitol.
  • the molecular weight of the alcohols should be less than about 1000. Mixtures of alcohols can likewise be used.
  • Glycerin is the preferred adjuvant because it has the attributes of a medicament, cosmetic or therapeutic agent.
  • the hydrophilic agent is starch-based, it is believed that glycerin coats the hydrophilic agent to form a starch glycerite.
  • fluid is absorbed by the foam, glycerin is released, thereby allowing the hydrophilic agent to swell as it absorbs fluid from the wound and causing the foam to conform to the wound contour.
  • Various additional medicaments, cosmetics and therapeutic agents may be carried with the adjuvant and released with it to the desired situs. This release thus allows the transmission of such therapeutic or other agents carried in the adjuvant to the area of application outside the foam composition, further assisting in the beneficial treatment of the wound.
  • Illustrative of therapeutic agents which may be incorporated into the foam composition are Collasol 2400, Crotein SPA, Cromoist HYA, Crotein CAA and hydrocortisone acetate.
  • Illustrative of cosmetic agents which may be incorporated into the foam composition are European Collagen Complex, Capture Complex Liposomes, Sardo® bath oil, a hand lotion sold under the trademark Jergens®, Noxema® skin cream, Oil of Olay® BF, Keri® lotion, Vaseline® herbal and aloe lotion, Ben Gay® ointment and Retin-A® cream.
  • the amount of adjuvant included in the reactant composition should preferably be sufficient to impart softness and pliability to the foam composition and be capable of delivering a therapeutic agent or the like, if included, to the environment of application.
  • the volume of adjuvant should not be so great as to weaken or gel the composition.
  • the amount of adjuvant in the reactant composition should be from about 5 wt.% to about 30 wt.% of the reactant composition.
  • a wetting agent is included in the reactant composition to provide more uniform wettability of the resulting foam.
  • the wetting agent also aids in controlling the cell size of the foam and in the reticulation of the final foam.
  • Wetting agents suitable for use include non-ionic surfactants. Examples of materials that may be used as the wetting agent, either alone or in admixture, include block copolymers of ethylene oxide and propylene oxide sold under the trademark PLURONIC by BASF Wyandotte corporation, ethoxylated sorbitan fatty acid esters, glycerol esters, polyglycerol esters, and silicone fluids.
  • PLURONIC F-68 and L-62 are preferred. As is known, PLURONIC F-68 aids in wound cleansing without causing tissue damage.
  • PLURONIC F-68 is especially preferred because of its cleansing action, particularly because a portion of the surfactant may be released when the foam composition is exposed to the exudate of the wound.
  • the amount of wetting agent should be from about 1% to about 10% by weight of the reactant composition, preferably from about 5% to about 7% by weight.
  • the wetting agent should not react with the foam composition or any component of the foam formulation to create difficulties during foam formation or to adversely affect the desired characteristics of the foam composition in use or while being stored.
  • the source of the water required for the foaming reaction is not critical.
  • the water so required may be provided as a separate component of the reactant composition, or, for example, it may be provided by one of the other components of the reactant composition.
  • the required water may be provided with an aqueous-based cosmetic which may be incorporated into the foam composition.
  • the type of water used is likewise not critical. However, for medical applications, purified water such as deionized or distilled water may be used. Saline solutions may also be used satisfactorily.
  • the relative proportion of prepolymer, adjuvant and hydrophilic agent included in the reactant composition can be varied over wide ranges in order to prepare a hydrophilic foam composition having the desired release and exchange characteristics previously described, while likewise providing a foam composition that is aesthetically satisfactory, insofar as its oilyness, touch, appearance and general feel.
  • the foam composition be soft and generally smooth to the touch so that it does not irritate the skin.
  • the resulting foam composition has an extended cure time with decreased ability to tightly hold external liquid and it may have an oily or spongy nonuniform surface.
  • the resulting foam composition has been found to be less uniform, has relatively poor flow and porosity characteristics, has relatively poor dimensional stability, and absorbs liquid at a slower rate.
  • the resulting product will not be satisfactory.
  • the amount of hydrophilic agent must be sufficient to absorb the external liquid and to promote the release of the adjuvant. If the amount of hydrophilic agent is too low, there is insufficient absorption of external liquid. On the other hand, if the amount of hydrophilic agent is too high, then the viscosity of the reactant composition will be too high for appropriate mixing.
  • the weight ratio of prepolymer to hydrophilic agent will desirably be in the range of from about 20:1 to about 20:10 and the ratio of prepolymer to adjuvant will desirably be in the range of from about 20:2 to about 20:30.
  • wetting agent employed and the amount thereof used may effect the characteristics of the resulting foam composition. It is generally desired that the wetting agent be used in an amount such that the foam is substantially uniform and readily wettable.
  • the organic phase comprises the isocyanate-capped prepolymer and optionally, but preferably, the hydrophilic agent.
  • the aqueous phase comprises the adjuvant, wetting agent, optionally the hydrophilic agent if it is not included in the organic phase, and other desired additives, such as, for example, dyes or the like to color the resulting foam. If a medicament, cosmetic or therapeutic agent is included in the reactant composition it will preferably be included in the aqueous phase.
  • the organic phase and aqueous phase are simply mixed at room temperature, the resulting mixture is then cast or extruded, and the foam will form.
  • a suitable substrate such as a plastic (e.g. in the form of a sheet, laminate or fibrous mat), paper, foil, or the like is provided and coated with a medically acceptable adhesive.
  • a suitable substrate such as a plastic (e.g. in the form of a sheet, laminate or fibrous mat), paper, foil, or the like is provided and coated with a medically acceptable adhesive.
  • a medically acceptable adhesive Such adhesives are generally well known to those skilled in the art.
  • the reactant composition as described herein is poured directly onto the adhesive where the foam is formed.
  • the foam may then be covered by a cover sheet if desired.
  • the resulting composite which comprises the substrate, adhesive, and foam may be die cut and later used itself, or it may be used as part of an occlusive or semi-occlusive wound dressing.
  • hydrophilic polyurethane foam composition was formulated by separately preparing an aqueous phase and an organic phase then mixing both phases at room temperature, and casting the mixture onto a film substrate.
  • the aqueous phase was prepared by dissolving the alcohol, wetting agent and colorant in distilled water using a laboratory grade magnetic stirrer. It should be noted that some surfactants (especially the paste types) required heating to 150°F before dissolution or even dispersion was possible. All other mixing was done at ambient temperature. When Pluronic F-68 was used, solution required about one hour of mixing at 1000 rpm on the stirrer to complete dissolution.
  • the organic phase was prepared by mixing the isocyanate-capped prepolymer and hydrophilic agent for about 5 to 10 seconds in a plastic vessel using an electric drill with a paint mixer blade.
  • the aqueous phase was poured into the organic phase contained in a suitable mixing vessel.
  • the two phases were then mixed using a drill with the paint mixer for about 15 to about 50 seconds at about 1200 rpm of the drill. Mixing time may be varied for different formulations, but generally mixing time was about 25 seconds.
  • the resulting mixture was evenly poured as a bead down a paper substrate coated with a medical grade adhesive, and covered with the silicone treated side of a 5 mil polystyrene sheet.
  • the paper substrate was about four inches wide and bordered by 0.025 inch plastic strips to contain the mixture during compression.
  • the bead was compressed and spread using a 30 pound steel cylinder.
  • the mixture was rolled at the rate of two inches per second first at 90 seconds after the two phases are combined and then after 120 seconds after combination. The foam was allowed to set for approximately seven minutes, then the cover sheet was removed.
  • the resulting foams varied in thickness from about 0.050 inch to about 0.10 inch and varied in density from about 10 to about 20 lbs/ft3.
  • Each of the foams of Examples 1-57 was tested to determine the release characteristics of the foam, especially the adjuvant, and to determine the ability of the foam to absorb external liquid.
  • the foams were immersed in one or more of the following: water, a normal saline solution, a 0.03% HCl solution and/or a 0.05% NaOH solution.
  • the pH of these solutions fall within the range of pH 2 to pH 12. Both the liquid held by the sample and the liquid tightly held by the sample were measured.
  • the liquid held by the sample is reported as retained liquid.
  • Retained liquid is the unit weight of liquid per unit weight of foam. It is determined by the formula:
  • Tightly held liquid is a measure of the relative amount of liquid retained by the sample after compression. It is determined by rolling an 8 pound roller over the sample ten times, and then, using the retained liquid formula to calculate the relative proportion of liquid that was not squeezed out of the composition.
  • the % extractables is measured in deionized water, normal saline, 0.03%HCl and/or 0.05%NaOH solutions. The percent extractable material is determined under static conditions at room temperature. In addition, the dehydrated extracted residues were visually examined for the adiuvant. In general, it was found that from about 90 to 95% of the adjuvant is released from the foam. In general, when deionized water was used, the pH of the extract was 7.0 ⁇ 1.0 pH units.
  • the absorption rate was determined for the foam compositions.
  • the absorption rate is the time, in seconds, for 0.1 g of fluid to be absorbed by the foam composition.
  • the fluid used was either deionized water, distilled water or normal saline. An absorption rate of less than 10 is satisfactory, and a rate of less than 5 is preferred.
  • Examples 1-8 illustrate variations in the amount of water and in the wetting agent used in the reactant composition.
  • Example 8 illustrates the wide range of the ratio of prepolymer to hydrophilic agent and prepolymer to adjuvant that can be employed in making the foam composition of this invention.
  • the reactant compositions are set forth in Table I below.
  • the foams of Examples 9-12, 17 and 18 were acceptable. However, the foams of Examples 13 and 15 exhibited gross porosity, while the foams of Examples 14 and 16 had excessively high absorption rates, and were thus more hydrophobic.
  • the foams of Examples 21 and 26 were acceptable as determined by all visual and measured properties. However, the foams of Examples 19 and 20 exhibit relatively poorer dimensional stability and a slower absorption rate. The foams of Examples 22-25 were less uniform than the preferred composition of Examples 1 and 2.
  • Example 27-32 The foams of Examples 27-32 were all acceptable by all criteria. However, the tightly held liquid of Example 29 is somewhat low.
  • Example 43-47 the water needed for the foaming reaction was provided by the water contained by the cosmetic.
  • the surfactant was also included in the cosmetic.
  • the foams of Examples 41 and 47 were less hydrophilic than desired as can be seen by their high absorption rates.
  • the foams of all the other Examples were satisfactory.
  • the foams of Examples 43-46 were especially soft and uniform with distinct cosmetic odor.
  • the foams of Examples 48, 50, 56 and 57 were acceptable.
  • the foams of Examples 51 through 54 were more porous than desired, although the liquid retention and extractability were good.
  • the amount of extractable material for the foam of Example 49 was somewhat low.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials For Medical Uses (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicinal Preparation (AREA)

Abstract

A hydrophilic foam composition comprising the in situ reaction product of an isocyanate-capped polyether prepolymer, a hydrophilic agent capable of absorbing water, an adjuvant comprising an alcohol, a wetting agent, and water. The composition releasably carries the adjuvant and will release at least a portion of the adjuvant in the presence of an external liquid so that the liquid can be absorbed and carried by the foam composition. The composition is particularly useful in wound dressings and composites for use in such dressings.

Description

  • The present invention relates to novel foam products and, more particularly, to highly absorbent hydrophilic polyurethane foam compositions which have liquid release and exchange characteristics.
  • Absorbent pads, such as for use in contact with the skin for absorbing body fluids, are well known. Such pads are useful for numerous applications, including for example as a diaper, sanitary napkin, bandage, wound dressing or the like.
  • Absorbent pads have been made of a wide variety of materials. For example, such pads have been made using graft copolymers, as described in U.S. 4,055,184. The absorbent pad therein described includes an absorbent mass comprising a solid finely-­divided mixture of a completely hydrolyzed starch-­polyacrylonitrile graft copolymer and a non-­irritating and non-toxic water-soluble basic material such as, for example, sodium bicarbonate which may be admixed with and distributed in a highly porous web or batt of cotton linters, layers of creped tissue or a mass of shredded polyurethane foam particles.
  • Pads in the form of a foam and which have been made from various superabsorbent materials are likewise known. For example, U.S. 4,394,930 discloses an absorbent foam product prepared by mixing together a solid, particulate, water-­insoluble, water-swellable polymer such as "hydrogels", "hydrocolloids" or "superabsorbents" which are lightly cross-linked polymers containing a plurality of hydrophilic groups, such as carboxyl, carboxamide, sulfonate salt or hydroxyl groups, a blowing agent, and a liquid polyhydroxy organic compound and allowing the mixture to foam.
  • Polyurethane foams, treated and/or prepared in a manner so as to render them hydrophilic are also known. For example, U.S. 3,586,648 discloses a hydrophilic polyurethane foam prepared by the so-­called "one-shot" technique and is stated to include a carboxymethyl cellulose or a carboxymethyl cellulose salt.
  • U.S. 4,497,914 discloses an ostomy gasket composition derived from the non-aqueous reaction of a polyisocyanate and a polyoxyalkylene polyol. A hydrophilic filler, such as hydroxyethylcellulose, hydroxypropylcellulose or mixtures thereof, are incorporated into the polyol phase prior to reaction.
  • Hydrophilic cross-linked polyurethane foams are disclosed in U.S. 3,903,232. Such foams are prepared by reacting particular isocyanate-capped polyoxyethylene polyols having an isocyanate functionality greater than two with large amounts of an aqueous reactant, preferably water. The foam is said to be useful for the absorption of body fluids and may be used for external body cleaning, for internal body usage, such as is necessary in dental and medical applications, and as intimate absorptive products such as diapers, sanitary napkins, catamenial devices and the like.
  • Other adsorbent pads using hydrophilic foam include U.S. 3,961,629, which discloses a hydrophilic polyurethane foam in which the foam pores have a surfactant coating to accelerate absorption of body fluids into the pores at medically acceptable rates. The foam is rendered hydrophilic by coating the pore walls with a thin layer of a surfactant. Hygroscopic agents such as glycerine as well as other agents, such as germicidal and therapeutic agents, may be incorporated into the foam.
  • U.S. 4,664,662 discloses an absorbent wound dressing which comprises an absorbent foam material retained in a water permeable, porous bag. The absorbent foam is preferably a hydrophilic polyurethane foam which can be made from HYPOL isocyanate-capped polyether prepolymer marketed by W.R. Grace and Co. and non-ionic surfactants. Physiologically active components such as local anaesthetics, antibacterial agents, antifungal agents and the like which are compatible with the absorbent material may be incorporated into the wound dressing.
  • Hydrophilic polyurethane foam compositions are also disclosed in U.S. 4,339,550. The hydrophilic foam composition is prepared by the "in situ" reaction of an isocyanate-capped polyether prepolymer having a functionality of from about 2 to about 8, water, and a chemically compatible, essentially non-­polar, volatile organic compound. The foam is stated to be capable of achieving a sustained, controlled release of the volatile materials from the foam structure. Suitable "control release" ingredients for use in controlling the rate of release of the volatile ingredients include polyols, such as propylene glycol and glycerin, and materials classified as gums.
  • Despite the wide variety of known absorbent pads and polyurethane foam compositions there still remains a need for a highly absorbent hydrophilic polyurethane foam composition which releasably carries an adjuvant and which is capable of both absorbing an external liquid and releasing the adjuvant carried by the foam composition in the presence of the external liquid.
  • Accordingly, it is a principal object of the present invention to provide a polyurethane foam composition which is hydrophilic, highly absorbent and which releasably carries an adjuvant which is capable of being released from the foam in the presence of an external liquid which is preferentially absorbed by the foam composition. A more detailed object of the present invention is to provide a foam composition which is capable of releasing an adjuvant to a designated situs and which is capable of absorbing external liquids from that situs. A related object is to provide such a polyurethane foam composition which will tightly hold the external fluid once it is absorbed.
  • Another object of the invention is to provide a hydrophilic foam composition that can be prepared at ambient temperature.
  • It is a further object of the present invention to provide a wound dressing using a highly absorbent hydrophilic polyurethane foam composition. It is yet another object of the present invention to provide such a foam composition which includes a therapeutic, cosmetic or other like agent for release to and treatment of the situs of application. A still further object is to provide a foam composition which has hemostatic, bacteriostatic, emollifying, demulcifying and wound cleansing properties.
  • It is yet another object to provide a method of treating a wound by applying to the wound a wound dressing which includes a hydrophilic foam composition as described herein.
  • A further object of the present invention is to provide a composite for use in a wound dressing which includes a hydrophilic foam composition as described herein. Another object is to provide a method for making such a composite.
  • These and other objects and advantages of the present invention will be apparent from the following description of the invention.
  • The present invention is predicated on the discovery that a highly absorbent hydrophilic polyurethane foam composition which releasably carries an adjuvant and is capable of releasing at least a portion of the adjuvant while preferentially absorbing external liquid upon exposure of the foam composition to the external liquid, can be made by incorporating a hydrophilic agent and a releasably carried adjuvant in the foam composition. Incorporation of the adjuvant in the resulting foam is achieved by the in situ reaction of a hydrophilic isocyanate-capped polyether prepolymer, a hydrophilic agent, water, adjuvant and a wetting agent.
  • Thus, in one aspect, the present invention provides a hydrophilic polyurethane foam composition comprising the in situ reaction product of an isocyanate-capped polyether prepolymer, a hydrophilic agent capable of absorbing water, an adjuvant comprising a mono or polyhydric alcohol, a wetting agent for enhancing the wettability of the foam composition, and water. The hydrophilic foam is capable of exchanging an external fluid and tightly carrying the external fluid in preference to at least a portion of the adjuvant so that upon exposure of the hydrophilic foam composition to an external fluid, such as, for example, to the exudate of a wound, the composition will absorb the external fluid and tightly carry it in preference to at least a portion of the adjuvant so that at least a portion of the adjuvant is released from the foam.
  • In another aspect, the present invention provides a novel wound dressing which incorporates the novel hydrophilic polyurethane foam. In yet another aspect, the present invention provides a method of treating a wound which includes applying to the wound the novel hydrophilic foam composition disclosed herein or a wound dressing made therefrom. In still other aspects of the invention, composites which include the hydrophilic foam composition described herein and a method for making such composites are provided.
  • While the invention will be described in connection with the preferred embodiments, it will be understood that the invention is not intended to be so limited. On the contrary, it is intended to cover all alternatives, modifications and equivalents as may be included within the spirit and scope of the invention as defined by the appended claims. As an example, while the present invention will be described herein in relation to the use of the highly absorbent hydrophilic foam composition as a wound dressing, it should be appreciated that the foam composition of this invention is likewise useful in other applications where it is desired to releasably carry an adjuvant to a situs for subsequent application and to absorb an external liquid, such as water, from the situs of application. Such uses include, for example, cosmetic applications.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • In accordance with the present invention there is provided a highly absorbent hydrophilic polyurethane foam composition which includes a releasably carried adjuvant which is capable of being emitted from the composition in the presence of an external liquid. The foam composition of this invention is the in situ reaction product of a reactant composition comprising an isocyanate-capped polyether prepolymer, a hydrophilic agent, an adjuvant, water and a surfactant or wetting agent.
  • In keeping with the invention, the hydrophilic foam composition, when applied to a moisture laden surface will preferentially absorb moisture from that surface while releasing the adjuvant carried by the composition. The hydrophilic polyurethane foam composition of the present invention is particularly useful as the absorbent pad of an occlusive or semi-­occlusive wound dressing, commonly applied to injuries such as abrasions, incisions, punctures, lacerations, ulcers, sores, burns and the like to aid in stopping bleeding and in protecting the wound from contamination.
  • When applied to a wound, the foam composition of the present invention will absorb and retain a high volume of aqueous fluid, i.e., wound exudate, and will release the adjuvant to the wound situs. By proper selection of the adjuvant and, optionally, additives, such as therapeutic agents, medicaments and the like incorporated into the foam and releasably carried with the adjuvant, a wound dressing which incorporates the foam composition of the present invention may be prepared which is advantageously capable of providing enhanced hemostatic and chemical debridement characteristics as well as transdermal, bacteriostatic, emollifying, demulcifying and wound cleansing characteristics.
  • Once affixed to the skin surface, the foam composition absorbs exudate moisture from the wound. In absorbing the exudate moisture, the foam swells to conform to the wound contour so as to become thermally insulative to the surface of application, while at the same time holding moisture against the surface in order to keep that surface moist. The foam composition will then assist in maintaining a warm, moist and sealed wound with appropriate pH to promote epidermal resurfacing and re-epithelization. A wound dressing which includes the foam composition of the present invention does not adhere to the wound and thus does not cause reinjury upon its removal from the wound. This is believed to be due to the liquid exchange and the maintenance of a moist environment about the wound.
  • The hydrophilic polyurethane foam compositions of the present invention are prepared using an isocyanate-capped polyether prepolymer. Generally, these prepolymers must be safe for use in the human body, and are preferably capable of foaming in an aqueous system in the absence of a catalyst. On the other hand, such prepolymers should not dissolve in the aqueous liquid. Additionally, it is highly desirable that these prepolymers cure to form a porous cellular foam matrix to enable both absorption of external fluids and carriage of the chosen adjuvant in the foam composition. The formation of a cellular foam matrix is preferred due to a large volume available not only for absorption but the containment of the chosen adjuvant. It is further desirable that the prepolymers are capable of curing in the presence of water, in the absence of catalyst, and at ambient temperature.
  • Isocyanate-capped polyether prepolymers such as those disclosed in U.S. Patent Nos. 3,903,232 and 4,137,200 are suitable for use in the present invention. These prepolymers have a defined average isocyanate functionality greater than 2. These prepolymers may be capped with aromatic isocyanates, such as, for example, toluene diisocyanate or methylene diphenyl isocyanate, or with aliphatic isocyanates, such as isophorone diisocyanate. Isocyanate-capped polyether prepolymers which have been found suitable for use in the practice of the present invention include prepolymers sold under the trademark HYPOL. Examples include HYPOL FHP 2000, HYPOL FHP 2002, HYPOL FHP 3000, HYPOL FHP 4000, HYPOL FHP 5000, HYPOL X6100 and HYPOL hydrogel.
  • HYPOL 2000, HYPOL 2002 and HYPOL 3000 prepolymers are derived from toluene diisocyanate. FHP 2000 and FHP 2002 both have an equivalent weight (per NCO) of 625, an NCO content of 1.60 meq/g and a specific gravity of 1.19. The viscosity of FHP 2000 is 18,500 cps (Brookfield LVF, #4 Spindle, 12 rpm at 25°C) and that of FHP 2002 is 20,000. FHP 3000 has an equivalent weight (per NCO) of 425, an NCO content of 2.35 meq/g, a specific gravity of 1.15 and a viscosity (measured as described above) of 10,500. HYPOL hydrogel is likewise derived from toluene diisocyanate. It has an NCO content of 0.5-0.9 meq/g and a viscosity of 10,000 to 12,000 cps at 25°C.
  • Another example of an isocyanate-capped prepolymer suitable for use in the present invention and derived from toluene diisocyanate is AQUAPOL prepolymer, commercially available from Freeman Chemical Corporation. AQUAPOL prepolymers have an NCO-value of 2.5 to 3.0 and are formed from the reaction of toluene diisocyanate and an organic polyether polyol containing at least 40 percent by weight ethylene oxide adducts as described at Col. 2, lines 3-22 of U.S. 4,517,326.
  • A further example of an isocyanate-capped prepolymer suitable for use in the present invention and which is derived from toluene diisocyanate is sold under the trademark TREPOL, and is commercially available from Twin Rivers Engineering. TREPOL prepolymers have an -NCO content of 1.4 milliequivalents per gram and a viscosity at 90°C of 4,700 cps.
  • The HYPOL FHP 4000 and HYPOL FHP 5000 prepolymers are derived from methylene diisocyanate. FHP 4000 has an equivalent weight (per NCO) of 476, an NCO content of 2.10 meq/g, a Brookfield viscosity (LVF, #4 Spindle, 12 r.p.m. at 25°C) of 20,000 and specific gravity of 1.17. FHP 5000 has an equivalent weight (per NCO) of 392, an NCO content of 2.55 meq/g, a Brookfield viscosity (measured as for FHP 4000) of 18,000 and a specific gravity of 1.17.
  • An example of an isocyanate-capped prepolymer suitable for use in the present invention and derived from isophorone diisocyanate is HYPOL X6100. It has an -NCO content of 1.8 meq/grams and a viscosity at 25°C of 12,000 cps.
  • The amount of prepolymer in the reactant composition used to prepare the hydrophilic foam composition is not particularly critical, but depends on a number of factors, including the proportion of other components in the reactant composition as will be described in greater detail hereinafter. However, there should be sufficient prepolymer to form a polyurethane foam, to releasably contain the adjuvant and to adequately contain the hydrophilic agent. To that end, the ratio of prepolymer to hydrophilic agent should be such that the reactant composition does not degrade or break up into its separate constituents. Furthermore, while there should be sufficient prepolymer to provide integrity to the foam matrix, there should not be so much prepolymer that the resulting polyurethane composition becomes unworkable. In short, and particularly where the final composition is to be applied to the skin, the resulting foam composition is desirably relatively smooth and soft while exhibiting the desired absorbence characteristics so that it does not irritate or otherwise harm the skin.
  • The concentration of prepolymer further depends on its isocyanate functionality and the degree of crosslinking desired in the final foam composition. In general, the greater the isocyanate functionality, the greater the degree of cross-linking in the cured foam matrix. Typically, the reactant composition will comprise from about 20% to about 60% by weight prepolymer. Preferably the reactant composition will comprise from about 45% to about 50% by weight of the prepolymer. Advantageously, the prepolymers may be used alone or in combination.
  • The reactant composition further includes a hydrophilic agent which is incorporated into the foam composition to absorb external liquid, such as wound exudate, and to retain such liquid in the composition. When applied to a wound, the hydrophilic agent is believed to work in conjunction with the foam matrix to hold moisture at the surface of the wound. This allows healing agents exuded by the wound to be concentrated and held at the wound surface. At the same time, the hydrophilic agent incorporated into the composition is believed to absorb fluid from the wound to assist thickening of the blood, i.e., it serves as a hemostat. The absorption of exudate by the hydrophilic agent, and the subsequent swelling of the agent results in the removal of inflammatory exudates and particles that would otherwise hinder tissue repair or cause eschar formation. Necrotic debris and bacteria are likewise removed as autolysis, i.e. chemical debridement is stimulated.
  • The hydrophilic agent is preferably a highly absorbent polymer, commonly known as a superabsorbent polymer. One measure of polymer absorbency is its fluid uptake capability, well known by those skilled in the art. Hydrophilic agents suitable for use in the present invention include polymers that are capable of absorbing at least 50 times their weight of water, that is, such agents have a fluid uptake of at least 50 ml/g. Hydrophilic agents having an even higher fluid uptake, such as of at least about 100 ml/g and even higher, that is, at least about 150 ml/g are preferred. Suitable superabsorbent polymers include sodium and aluminum salts of starch grafted copolymers of acrylates and acrylamides and combinations thereof, as well as polyacrylate salts. Of course, other absorbent materials may be used in combination with such highly absorbent polymers, provided the fluid uptake of the overall combination used for the hydrophilic agent is greater than 50 ml/g. When such agents are employed, either alone or in combination, the resulting foam composition desirably has the ability to hold at least about 3 times its weight in liquid. In the preferred embodiment, the resulting foam composition will have the ability to tightly hold at least about 3 times its weight in fluid. As used herein "tightly hold" or "tightly bound" liquid means the relative amount of liquid retained by the sample after compression, as described in detail hereinafter.
  • Hydrophilic polymers which have been found suitable for use in the foam composition of this invention are commercially available from Grain Processing Corporation. These polymers include a starch-g-poly(2-propenamide-co-2-propenoic acid, mixed sodium and aluminum salt) sold under the trademark WATER LOCK A-222; a starch-graft copolymer of polyacrylic acid and polyacrylamide having the chemical name starch-g-poly(2-propenamide-co-2-­propenoic acid, sodium salt), sold under the trademark WATER LOCK A-100; a starch g-poly(2-­propenamide-co-2-propenoic acid, sodium salt), sold under the trademark WATER LOCK A-200. Superabsorbent polymers commercially available from Grain Processing Corporation under the trademark WATER LOCK D-212 and WATER LOCK D-242 are likewise suitable. These polymers have the chemical name starch-g-poly(2-­propenamide-co-2-propenoic acid, mixed sodium and aluminum salt). The superabsorbent polymer commercially available under the trademark WATER LOCK G-400 is also suitable for use in the making of the hydrophilic foam composition of the present invention. This superabsorbent polymer may be chemically identified as a poly(2-propenamide-co-2-­propenoic acid, sodium salt). Other super absorbent powders suitable for use in the present invention are sold by Grain Processing Corporation under the trademark WATER LOCK B, C, and H.
  • Another example of a suitable superabsorbent polymer is poly-2-propenoic acid, sodium salt, sold under the trademark AQUA KEEP J-500 supplied by Sanyo Corp. In addition, super absorbent polymers sold by Arakawa Chemical (USA) Inc. under the trademark ARASORB are suitable. The preferred hydrophilic polymers are WATER LOCK A-100, A-200, A-222 and AQUA KEEP J-500. The hydrophilic polymers may be used alone, or in combination to achieve the desired absorptivity characteristics in the foam composition.
  • The hydrophilic agent may comprise additives in addition to the superabsorbent polymers, provided, as discussed above, the additives do not reduce the fluid uptake of the hydrophilic agent to below about 50 ml water per gram of hydrophilic agent and the fluid uptake of the final foam composition is not less than about 3 times its weight. Examples of such additives include methylcellulose, guar gum, pectin, karaya gum, chitosan, agar, acacia powder, carrageenan, gelatin and combinations thereof.
  • The amount of hydrophilic agent used and the type of it, in terms of its fluid uptake, that may be satisfactorily used to make the foam composition is not critical, but is, instead, dependent on the intended application of the composition. Stated another way, the greater the quantity of external liquid to be absorbed, e.g., the greater the amount of wound exudate, the greater the amount of hydrophilic agent that should be employed. In the alternative, the greater the amount of wound exudate to be absorbed, the greater the fluid uptake of the hydrophilic agent used, should be. For example, for an ulcerated wound where there is a high volume of wound exudate, a hydrophilic agent with high uptake is desirable. In addition, it may well be determined that the amount of hydrophilic agent may need to be increased. On the other hand, where the foam is to be applied to a small cut or light burn it may be suitable to use less hydrophilic agent or to use a hydrophilic agent with a lower fluid uptake. Determination of the type and amount of hydrophilic agent used is well within the ability of one skilled in the art in light of the disclosure herein.
  • The amount of hydrophilic agent should not be so great as to undesirably reduce the strength of the foam composition or result in a loss of polymer from the foam, although some loss of hydrophilic agent may be tolerated without adversely affecting the ability of the foam to absorb external liquid. The amount of hydrophilic agent employed in the reactant composition will also depend on the absorbency of the material used. As previously indicated, it is preferable that a sufficient amount of hydrophilic agent be employed so that the resulting foam composition is capable of absorbing at least about 3 times its weight in external liquid. Typically this can be achieved by including from about 5 wt.% to about 20 wt.% hydrophilic agent in the reactant composition.
  • The reactant composition of this invention further includes an adjuvant; preferably, a water-­soluble adjuvant. The adjuvant is releasably carried by the resulting foam composition for subsequent release to a chosen situs of application. Release of the adjuvant occurs in the presence of an external liquid, such as wound exudate, which is preferentially absorbed by the foam composition. Absorption of the external liquid causes at least a portion of the adjuvant to be released.
  • It will be appreciated by those skilled in the art that not all of the liquid adjuvant is necessarily released (or need it be) in the presence of the external fluid. However, a sufficient amount of adiuvant must be released in order to achieve the desired result. To that end, it will be appreciated that the efficacy of the adjuvant is realized upon its release from the foam composition to the situs of application. In the case of a wound dressing, the situs is the wound, burn or the like, itself. Release of the adjuvant thus provides beneficial treatment to the wound.
  • Prior to curing, the adjuvant serves as a plasticizer for the reactant composition. It extends the curing time of the composition thereby allowing it to be more thoroughly mixed and formed. Once cured, the foam composition is softened by the adjuvant, allowing the foam to be more pliable and more easily applied to the skin surface or other surface of choice. Additionally, the adjuvant may be somewhat hygroscopic lending further to the hydrophilic nature of the foam composition.
  • Adjuvants suitable for use in the foam composition of the present invention are mono, di and polyhydric alcohols. Preferably the adjuvants are water soluble so that they may be readily released from the composition upon contact of the foam composition with an external liquid. For wound dressing applications, it is also desirable that the adjuvant be capable of contacting skin without adverse side effects. To that end, it is also preferable that the adjuvant comprise a chemical compound that will have the ability to open the skin pores to achieve a demulcent effect to relieve pain and/or irritation and to achieve an emollient effect to soften the skin and prevent maceration. It is also preferred that the adjuvant be compatible with therapeutic or other agents which may be carried by the adiuvant for subsequent delivery to the situs of application. Suitable adjuvants include water soluble alcohols, including monols, diols and polyhydric alcohols. Examples of monols include ethyl alcohol and isopropyl alcohol. Exemplary of suitable diols are propylene glycol, polyethylene glycol and polypropylene glycol. Exemplary of suitable polyhydric alcohols are glycerin, 1,2,4-­butanetriol, trimethylolpropane, pentaerythritol and sorbitol. In general, the molecular weight of the alcohols should be less than about 1000. Mixtures of alcohols can likewise be used.
  • Glycerin is the preferred adjuvant because it has the attributes of a medicament, cosmetic or therapeutic agent. When glycerin is used and the hydrophilic agent is starch-based, it is believed that glycerin coats the hydrophilic agent to form a starch glycerite. When fluid is absorbed by the foam, glycerin is released, thereby allowing the hydrophilic agent to swell as it absorbs fluid from the wound and causing the foam to conform to the wound contour.
  • Various additional medicaments, cosmetics and therapeutic agents may be carried with the adjuvant and released with it to the desired situs. This release thus allows the transmission of such therapeutic or other agents carried in the adjuvant to the area of application outside the foam composition, further assisting in the beneficial treatment of the wound.
  • Illustrative of therapeutic agents which may be incorporated into the foam composition are Collasol 2400, Crotein SPA, Cromoist HYA, Crotein CAA and hydrocortisone acetate. Illustrative of cosmetic agents which may be incorporated into the foam composition are European Collagen Complex, Capture Complex Liposomes, Sardo® bath oil, a hand lotion sold under the trademark Jergens®, Noxema® skin cream, Oil of Olay® BF, Keri® lotion, Vaseline® herbal and aloe lotion, Ben Gay® ointment and Retin-A® cream.
  • The amount of adjuvant included in the reactant composition should preferably be sufficient to impart softness and pliability to the foam composition and be capable of delivering a therapeutic agent or the like, if included, to the environment of application. However, the volume of adjuvant should not be so great as to weaken or gel the composition. Generally, it has been found that the amount of adjuvant in the reactant composition should be from about 5 wt.% to about 30 wt.% of the reactant composition.
  • A wetting agent is included in the reactant composition to provide more uniform wettability of the resulting foam. The wetting agent also aids in controlling the cell size of the foam and in the reticulation of the final foam. Wetting agents suitable for use include non-ionic surfactants. Examples of materials that may be used as the wetting agent, either alone or in admixture, include block copolymers of ethylene oxide and propylene oxide sold under the trademark PLURONIC by BASF Wyandotte corporation, ethoxylated sorbitan fatty acid esters, glycerol esters, polyglycerol esters, and silicone fluids. PLURONIC F-68 and L-62 are preferred. As is known, PLURONIC F-68 aids in wound cleansing without causing tissue damage. The use of PLURONIC F-68 is especially preferred because of its cleansing action, particularly because a portion of the surfactant may be released when the foam composition is exposed to the exudate of the wound. Generally, the amount of wetting agent should be from about 1% to about 10% by weight of the reactant composition, preferably from about 5% to about 7% by weight.
  • The wetting agent should not react with the foam composition or any component of the foam formulation to create difficulties during foam formation or to adversely affect the desired characteristics of the foam composition in use or while being stored.
  • It should be appreciated that the source of the water required for the foaming reaction is not critical. The water so required may be provided as a separate component of the reactant composition, or, for example, it may be provided by one of the other components of the reactant composition. By way of illustration, and not in limitation, the required water may be provided with an aqueous-based cosmetic which may be incorporated into the foam composition.
  • The type of water used is likewise not critical. However, for medical applications, purified water such as deionized or distilled water may be used. Saline solutions may also be used satisfactorily.
  • It will be appreciated that the relative proportion of prepolymer, adjuvant and hydrophilic agent included in the reactant composition can be varied over wide ranges in order to prepare a hydrophilic foam composition having the desired release and exchange characteristics previously described, while likewise providing a foam composition that is aesthetically satisfactory, insofar as its oilyness, touch, appearance and general feel. In general, for use as a wound dressing, it is preferable that the foam composition be soft and generally smooth to the touch so that it does not irritate the skin. These characteristics may be achieved by properly balancing the relative proportion of adjuvant, prepolymer hydrophilic agent wetting agent and water.
  • By way of illustration, it has been found that if excess glycerin is used in the reactant composition the resulting foam composition has an extended cure time with decreased ability to tightly hold external liquid and it may have an oily or spongy nonuniform surface. On the other hand, if insufficient glycerin is included in the reactant composition, the resulting foam composition has been found to be less uniform, has relatively poor flow and porosity characteristics, has relatively poor dimensional stability, and absorbs liquid at a slower rate.
  • Similarly, if the relative proportion of prepolymer to hydrophilic agent is too high or too low, the resulting product will not be satisfactory. The amount of hydrophilic agent must be sufficient to absorb the external liquid and to promote the release of the adjuvant. If the amount of hydrophilic agent is too low, there is insufficient absorption of external liquid. On the other hand, if the amount of hydrophilic agent is too high, then the viscosity of the reactant composition will be too high for appropriate mixing.
  • In general, in order for the foam composition to have the desired liquid release and exchange characteristics and to provide a foam composition that is soft to the touch and not oily, the weight ratio of prepolymer to hydrophilic agent will desirably be in the range of from about 20:1 to about 20:10 and the ratio of prepolymer to adjuvant will desirably be in the range of from about 20:2 to about 20:30.
  • It will likewise be appreciated that the wetting agent employed and the amount thereof used may effect the characteristics of the resulting foam composition. It is generally desired that the wetting agent be used in an amount such that the foam is substantially uniform and readily wettable.
  • To effect foaming and the preparation of the hydrophilic polyurethane foam composition of the present invention it is preferred to prepare and mix an organic phase and an aqueous phase. The organic phase comprises the isocyanate-capped prepolymer and optionally, but preferably, the hydrophilic agent. The aqueous phase comprises the adjuvant, wetting agent, optionally the hydrophilic agent if it is not included in the organic phase, and other desired additives, such as, for example, dyes or the like to color the resulting foam. If a medicament, cosmetic or therapeutic agent is included in the reactant composition it will preferably be included in the aqueous phase. To prepare the foam, the organic phase and aqueous phase are simply mixed at room temperature, the resulting mixture is then cast or extruded, and the foam will form.
  • To prepare the foam for subsequent use in a wound dressing or the like the following process is preferred. A suitable substrate, such as a plastic (e.g. in the form of a sheet, laminate or fibrous mat), paper, foil, or the like is provided and coated with a medically acceptable adhesive. Such adhesives are generally well known to those skilled in the art. Then the reactant composition as described herein is poured directly onto the adhesive where the foam is formed. The foam may then be covered by a cover sheet if desired. The resulting composite which comprises the substrate, adhesive, and foam may be die cut and later used itself, or it may be used as part of an occlusive or semi-occlusive wound dressing.
  • The following examples will aid in demonstrating the present invention.
  • In all of the examples which follow a hydrophilic polyurethane foam composition was formulated by separately preparing an aqueous phase and an organic phase then mixing both phases at room temperature, and casting the mixture onto a film substrate.
  • The aqueous phase was prepared by dissolving the alcohol, wetting agent and colorant in distilled water using a laboratory grade magnetic stirrer. It should be noted that some surfactants (especially the paste types) required heating to 150°F before dissolution or even dispersion was possible. All other mixing was done at ambient temperature. When Pluronic F-68 was used, solution required about one hour of mixing at 1000 rpm on the stirrer to complete dissolution.
  • The organic phase was prepared by mixing the isocyanate-capped prepolymer and hydrophilic agent for about 5 to 10 seconds in a plastic vessel using an electric drill with a paint mixer blade.
  • To prepare the foam composition, the aqueous phase was poured into the organic phase contained in a suitable mixing vessel. The two phases were then mixed using a drill with the paint mixer for about 15 to about 50 seconds at about 1200 rpm of the drill. Mixing time may be varied for different formulations, but generally mixing time was about 25 seconds.
  • The resulting mixture was evenly poured as a bead down a paper substrate coated with a medical grade adhesive, and covered with the silicone treated side of a 5 mil polystyrene sheet. The paper substrate was about four inches wide and bordered by 0.025 inch plastic strips to contain the mixture during compression. The bead was compressed and spread using a 30 pound steel cylinder. The mixture was rolled at the rate of two inches per second first at 90 seconds after the two phases are combined and then after 120 seconds after combination. The foam was allowed to set for approximately seven minutes, then the cover sheet was removed.
  • The resulting foams varied in thickness from about 0.050 inch to about 0.10 inch and varied in density from about 10 to about 20 lbs/ft³.
  • Definitions:
  • As used in the Examples appearing below, the following designations, symbols, terms and abbreviations have the indicated meanings:
  • I. Prepolymers: Prepolymer A
  • denotes an isocyanate-capped polyoxyethylene polyol polyurethane prepolymer derived from toluene diisocyanate having an equivalent weight (per-NCO group) of 625, an NCO content of 1.6 meq/gram, a functionality (-NCO/mole) of 2.3 and a viscosity at 25°C of 20,000 cps. (HYPOL 2002)
  • Prepolymer B
  • denotes an isocyanate-capped polyoxyethylene polyol polyurethane prepolymer derived from toluene diisocyanate having an NCO content of 0.5-0.9 meq/g. and a viscosity at 25°C of 10,000 to 12,000 cps. (HYPOL HYDROGEL)
  • Prepolymer C
  • denotes an isocyanate-capped polyoxyethylene polyol polyurethane prepolymer derived from isophorone diisocyanate having an NCO content of 1.8 meq/gram and a viscosity at 25°C of 12,000 cps. (HYPOL X6100)
  • Prepolymer D
  • denotes an isocyanate-capped polyoxyethylene polyol polyurethane prepolymer derived from toluene diisocyanate having an -NCO content of 1.4 meq/gram and a viscosity at 90°C of 4,700 cps. (TREPOL)
  • Prepolymer E
  • denotes an isocyanate-capped polyoxyethylene polyol polyurethane prepolymer derived from methylenediphenyl diisocyanate having an NCO content of 2.55 meq/g, an equivalent weight (per-NCO group) of 392 and a viscosity at 25°C of 18,000 cps. (HYPOL FHP 5000)
  • Prepolymer F
  • denotes an isocyanate-capped polyoxyethylene polyol polyurethane prepolymer derived from methylenediphenyl diisocyanate having an equivalent weight (per-NCO group) of 476, an -NCO content of 2.10 meq/g and a viscosity at 25°C of 20,000 cps. (HYPOL FHP 4000)
  • Prepolymer G
  • denotes a diisocyanate prepolymer derived from toluene diisocyanate sold under the trademark AQUAPOL 035-0019 by Freeman Chemical Corporation.
  • II. Hydrophilic agents:
    • A denotes a starch-g-poly(2-propenamide-co-2-­propenoic acid, mixed sodium and aluminum salt) sold under the trademark WATER LOCK superabsorbent polymer A-222.
    • B denotes a starch-g-poly(2-propenamide-co-2-­propenoic acid, sodium salt) sold under the trademark WATER LOCK superabsorbent polymer A-200.
    • C denotes a starch-g-poly(2-propenamide-co-2-­propenoic acid, sodium salt) sold under the trademark WATER LOCK superabsorbent polymer A-100.
    • D denotes a polymer consisting of 2-propenoic acid, sodium salt sold under the trademark WATER LOCK superabsorbent polymer J-500.
    • E denotes an absorbent polymer sold under the trademark ARASORB.
    • F denotes a polyacrylic acid, sodium salt sold under the trademark AQUA KEEP J-500.
    III. Absorption and Extraction Test:
  • Each of the foams of Examples 1-57 was tested to determine the release characteristics of the foam, especially the adjuvant, and to determine the ability of the foam to absorb external liquid. The foams were immersed in one or more of the following: water, a normal saline solution, a 0.03% HCl solution and/or a 0.05% NaOH solution. The pH of these solutions fall within the range of pH 2 to pH 12. Both the liquid held by the sample and the liquid tightly held by the sample were measured.
  • The liquid held by the sample is reported as retained liquid. Retained liquid is the unit weight of liquid per unit weight of foam. It is determined by the formula:
    Figure imgb0001
  • Tightly held liquid is a measure of the relative amount of liquid retained by the sample after compression. It is determined by rolling an 8 pound roller over the sample ten times, and then, using the retained liquid formula to calculate the relative proportion of liquid that was not squeezed out of the composition.
  • To determine whether the adjuvant is efficiently released from the foam, the % extractables is measured in deionized water, normal saline, 0.03%HCl and/or 0.05%NaOH solutions. The percent extractable material is determined under static conditions at room temperature. In addition, the dehydrated extracted residues were visually examined for the adiuvant. In general, it was found that from about 90 to 95% of the adjuvant is released from the foam. In general, when deionized water was used, the pH of the extract was 7.0 ± 1.0 pH units.
  • The absorption rate was determined for the foam compositions. The absorption rate is the time, in seconds, for 0.1 g of fluid to be absorbed by the foam composition. The fluid used was either deionized water, distilled water or normal saline. An absorption rate of less than 10 is satisfactory, and a rate of less than 5 is preferred.
  • The data for these studies is set forth in Tables immediately following the Examples.
  • Unless otherwise noted, for the compositions set forth in the Tables hereinafter all parts are in part by weight.
  • Examples 1-8
  • These Examples illustrate reactant compositions used to make hydrophilic foams of the present invention. Examples 1-8 illustrate variations in the amount of water and in the wetting agent used in the reactant composition. Example 8 illustrates the wide range of the ratio of prepolymer to hydrophilic agent and prepolymer to adjuvant that can be employed in making the foam composition of this invention. The reactant compositions are set forth in Table I below.
  • The retained liquid, tightly held liquid, extractable materials and absorption rate for the foam compositions of Examples 1 through 8 are set forth in Table II. TABLE I
    REACTANT COMPOSITION EXAMPLE No.
    1 2 3 4 5 6 7 8
    I. PREPOLYMER
    Prepolymer A 20.00 20.00 20.00 20.00 20.00 20.00 20.00 9.00
    II. HYDROPHILIC AGENT
    A 2.00 2.00 2.00 2.00 2.00 2.00 2.00 3.00
    III. WATER 14.50 10.00 14.50 10.00 12.25 15.00 13.00 18.00
    IV. ADJUVANT SYSTEM
    glycerin 5.00 5.00 5.00 5.00 5.00 5.00 5.00 15.00
    V. WETTING AGENT
    Pluronic F-68 2.50 1.25
    Pluronic L-62 1.00 0.50 0.70
    Pluronic F-88 2.50
    Pluronic L-92 1.00
    TMAZ 85 sorbitan trioleate 2.00
    Mazol 80 MG-K 2.00
    VI. DYES/DEFOAMING AGENTS
    FD&C Blue No. 1 Solution 0.05 0.05 0.025
    FD&C Red No. 3 & 40 Solution 0.025
    TABLE II
    EXAMPLE NO. 1 2 3 4 5 6 7 8
    RETAINED LIQUID
    Water 5.4 5.3 6.1 6.4 5.6 6.2 5.9 7.1
    Tightly Held Water 3.3 2.9 2.8 3.3 3.0 3.4 3.0 4.9
    % Extractable Material 22.0 19.0 21.0 20.0 20.0 16.0 18.0 46.0
    Saline 3.9 3.6 --- --- 3.6 4.4 --- ---
    Tightly Held Saline 1.3 1.4 --- --- 1.4 1.4 --- ---
    % Extractable Material 22.5 19.6 --- --- 19.0 16.0 --- ---
    0.03%HCl Solution 4.0 3.6 3.8 4.0 3.3 --- --- ---
    Tightly Held 0.03%HCl Solution 0.92 0.97 0.89 0.87 0.95 --- --- ---
    % Extractable Material 22.7 18.6 23.0 22.0 20.0 --- --- ---
    0.05% NaOH 5.2 4.9 5.1 5.8 4.7 --- --- ---
    Tightly Held 0.05% NaOH 2.6 2.4 2.3 2.8 2.4 --- --- ---
    % Extractable Material 21.2 18.2 22.0 19.2 19.0 --- --- ---
    ABSORPTION RATE 3.0 3.0 2.0 3.5 1.0 6.0 1.0 2.5
  • As can be seen by the data in Tables I and II, all of the foams were satisfactory according to the desired physical and chemical criteria. The foams of Examples 1 and 2 are preferred.
  • EXAMPLES 9-18
  • These Examples illustrate reactant compositions suitable for preparing hydrophilic foam compositions of the present invention wherein various adjuvants and combinations of adjuvants are used. The reactant compositions are set forth in Table III.
  • The retained liquid, tightly held liquid, extractable materials and absorption rate for the foam compositions of Examples 9 through 18 are set forth in Table IV. TABLE III
    REACTANT COMPOSITION EXAMPLE No.
    9 10 11 12 13 14 15 16 17 18
    I. PREPOLYMER
    Prepolymer A 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00
    II. HYDROPHILIC AGENT
    A 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00
    III. WATER 14.50 14.50 14.50 14.50 14.50 14.50 14.50 14.50 14.50 14.50
    IV. ADJUVANT SYSTEM
    1,2,4-butanetriol 5.00
    trimethylol propane 5.00
    glycerin 4.00 2.50 2.50 4.00 4.50
    polypropylene glycol 500 1.00 5.00 2.50 1.00
    propylene glycol 2.50 5.00
    ethyl alcohol 5.00
    pentaerythritol 0.50
    V. WETTING AGENT
    Pluronic F-68 2.50 2.50 2.50 2.50 2.50 2.50 2.50 2.50 2.50 2.50
    VI. OTHER
    FD&C Blue No. 1 Solution 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
    TABLE IV
    EXAMPLE NO. 9 10 11 12 13 14 15 16 17 18
    RETAINED LIQUID
    Water 4.7 5.9 4.4 5.9 5.1 4.7 7.6 3.8 4.4 6.6
    Tightly Held Water 2.8 3.6 2.8 2.9 3.0 4.3 4.8 3.3 2.8 2.8
    % Extractable Material 23.0 19.0 22.2 17.0 17.5 19.0 11.1 15.0 22.2 21.0
    Saline 3.4 3.4 3.4 --- 3.7 2.9 3.9 3.0 3.4 ---
    Tightly Held Saline```` 1.3 1.5 1.5 --- 1.5 2.4 2.2 1.9 1.5 ---
    % Extractable Material 22.0 18.0 19.6 --- 17.4 16.5 7.2 14.0 19.6 ---
    ABSORPTION RATE 5.5 4.5 4.5 2.0 2.0 >60 2.5 >60 4.5 2.0
  • The foams of Examples 9-12, 17 and 18 were acceptable. However, the foams of Examples 13 and 15 exhibited gross porosity, while the foams of Examples 14 and 16 had excessively high absorption rates, and were thus more hydrophobic.
  • EXAMPLES 19-26
  • These Examples illustrate reactant compositions suitable for preparing hydrophilic foam compositions of the present invention wherein various prepolymers and mixtures of prepolymers are used in the reactant composition. The reactant compositions are set forth in Table V.
  • The retained liquid, tightly held liquid, extractable materials and absorption rate for the foam compositions of Examples 19 through 26 are set forth in Table VI. TABLE V
    REACTANT COMPOSITION EXAMPLE No.
    19 20 21 22 23 24 25 26
    I. PREPOLYMER
    Prepolymer A 15.00
    Prepolymer B 20.00 5.00 10.00 10.00
    Prepolymer C 10.00
    Prepolymer D 20.00 10.00
    Prepolymer E 20.00
    Prepolymer F 20.00
    Prepolymer G 20.00
    II. HYDROPHILIC AGENT
    A 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.50
    D 2.00 0.50
    III. WATER 14.50 14.50 14.50 10.00 14.50 14.50 14.50
    Normal saline, 0.85% NaCl 14.50
    IV. ADJUVANT SYSTEM
    glycerin 5.00 5.00 5.00 5.00 5.00 10.00 5.00 10.00
    honey 0.50 0.50
    V. WETTING AGENT
    Pluronic F-68 2.50 2.50 2.50 2.50 2.50 2.50 2.50
    Pluronic L-92 1.00
    VI. OTHER
    FD&C Blue No. 1 Solution 0.05 0.05 0.05 0.05 0.05 0.05 0.05
    TABLE VI
    EXAMPLE NO. 19 20 21 22 23 24 25 26
    RETAINED LIQUID
    Water 7.1 5.4 5.9 3.1 3.8 8.5 7.9 10.0
    Tightly Held Water 5.9 4.9 2.9 2.5 2.2 6.0 4.8 6.6
    % Extractable Material 20.2 16.0 21.2 18.0 21.0 30.0 21.0 24.2
    Saline 5.8 4.0 --- --- --- --- --- ---
    Tightly Held Saline 4.5 3.6 --- --- --- --- --- ---
    % Extractable Material 16.2 12.4 --- --- --- --- --- ---
    ABSORPTION RATE 4.0 >60 3.0 1.0 1.0 75 2.5 2.5
  • The foams of Examples 21 and 26 were acceptable as determined by all visual and measured properties. However, the foams of Examples 19 and 20 exhibit relatively poorer dimensional stability and a slower absorption rate. The foams of Examples 22-25 were less uniform than the preferred composition of Examples 1 and 2.
  • EXAMPLES 27-32
  • These Examples illustrate the wide variety of hydrophilic agents that may be suitably employed in the reactant composition used to prepare the hydrophilic foam compositions of the present invention. The reactant compositions are set forth in Table VII.
  • The retained liquid, tightly held liquid, extractable materials and absorption rate for the foam compositions of these Examples are set forth in Table VIII. TABLE VII
    REACTANT COMPOSITION EXAMPLE No.
    27 28 29 30 31 32
    I. PREPOLYMER
    Prepolymer A 20.00 20.00 20.00 20.00 20.00 20.00
    II. HYDROPHILIC AGENT
    D 2.00
    C 4.00
    E 2.00
    Carrageenan 2.00
    A 2.00 2.00
    poly D-glucosamine 1.00
    pectin 2.00
    III. WATER 14.50 14.50 10.00 10.00 14.50 10.00
    IV. ADJUVANT SYSTEM
    glycerin 5.00 5.00 5.00 5.00 5.00 5.00
    V. WETTING AGENT
    Pluronic F-68 2.50 2.50 1.10 2.50 2.50
    Pluronic L-62 1.00
    VI. OTHER
    FD&C Blue No. 1 Solution 0.05 0.05 0.05
    FD&C Red No. 3 & 40 Solution 0.05 0.05 0.05
    10% Dimethylpolysiloxane 0.10
    TABLE VIII
    EXAMPLE NO. 27 28 29 30 31 32
    RETAINED LIQUID
    Water 8.2 9.4 4.7 8.8 5.3 7.5
    Tightly Held Water 6.6 6.0 0.92 4.5 2.8 2.5
    % Extractable Material 20.7 20.7 --- --- 22.0 ---
    Saline --- --- --- --- 3.9 ---
    Tightly Held Saline --- --- --- --- 1.3 ---
    % Extractable Material --- --- --- --- 21.0 ---
    ABSORPTION RATE 2.0 1.0 2.0 3.5 2.0 4.5
  • The foams of Examples 27-32 were all acceptable by all criteria. However, the tightly held liquid of Example 29 is somewhat low.
  • EXAMPLES 33-37
  • These Examples illustrate the addition of therapeutic agents suitable for use in wound dressing applications to the adjuvant of the reactant composition used to prepare hydrophilic foam compositions of the present invention. The reactant compositions are set forth in Table IX.
  • The retained liquid, tightly held liquid, extractable materials and absorption rate for the foam compositions of these Examples are set forth in Table X. TABLE IX
    REACTANT COMPOSITION EXAMPLE No.
    33 34 35 36 37
    I. PREPOLYMER
    Prepolymer A 20.00 20.00 20.00 20.00 20.00
    II. HYDROPHILIC AGENT
    A 2.00 2.00 2.00 2.00 2.00
    III. WATER 14.50 14.50 14.50 14.50 14.50
    IV. ADJUVANT SYSTEM
    glycerin 5.00 5.00 5.00 5.00 5.00
    Collasol 2400 2.00
    Crotein SPA 2.00
    Cromoist HYA 2.00
    Crotein CAA 2.00
    Hydrocortisone acetate, 0.5% 2.00
    V. WETTING AGENT
    Pluronic F-68 2.50 2.50 2.50 2.50 2.50
    VI. OTHER
    FD&C Blue No. 1 Solution 0.05 0.05 0.05 0.05 0.05
    TABLE X
    EXAMPLE NO. 33 34 35 36 37
    RETAINED LIQUID
    Water 5.6 6.8 6.4 5.7 6.6
    Tightly Held Water 2.6 2.7 2.8 2.3 2.7
    % Extractable Material 23.0 24.0 20.0 29.0 21.0
    ABSORPTION RATE 2.0 2.0 3.0 2.0 4.0
  • As can be seen by the data, all the foams of Examples 33-37 were acceptable.
  • EXAMPLES 38-47
  • These Examples illustrate the addition of cosmetic agents suitable for use in the hydrophilic foam compositions of the present invention. The reactant compositions are set forth in Table XI.
  • In Examples 43-47 the water needed for the foaming reaction was provided by the water contained by the cosmetic. The surfactant was also included in the cosmetic.
  • The retained liquid, tightly held liquid, extractable materials and absorption rate for the foam compositions of these Examples are set forth in Table XII. TABLE XI
    REACTANT COMPOSITION EXAMPLE No.
    38 39 40 41 42 43 44 45 46 47
    I. PREPOLYMER
    Prepolymer A 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 10.00
    II. HYDROPHILIC AGENT
    A 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 1.00
    III. WATER 14.50 14.50 14.50 14.50 14.50 --- --- --- --- ---
    IV. ADJUVANT SYSTEM
    glycerin 2.50 4.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 2.50
    European Collagen Complex 2.50
    Capture Complex Liposomes 1.00
    Sardo bath oil 2.00
    Jergens lotion 2.00
    Noxema skin cream 2.00
    Oil of Olay BF 20.00
    Keri lotion 20.00
    Vaseline Herbal & Aloe lotion 20.00
    Ben Gay ointment 20.00
    Retin-A cream 10.00
    V. WETTING AGENT
    Pluronic F-68 2.50 2.50 2.50 2.50 2.50 --- --- --- ---
    VI. OTHER
    FD&C Blue No. 1 Solution 0.05 0.05 0.05 0.05 0.05 --- --- --- ---
    TABLE XII
    EXAMPLE NO. 38 39 40 41 42 43 44 45 46 47
    RETAINED LIQUID
    Water 5.2 5.3 6.1 6.7 6.2 6.2 6.3 5.9 6.5 6.0
    Tightly Held Water 3.0 2.9 2.8 3.0 2.8 3.0 2.9 3.2 3.3 3.0
    % Extractable Material 15.0 19.0 22.0 22.0 25.0 14.0 24.2 16.0 22.0 15.0
    ABSORPTION RATE 8.5 3.0 2.0 16 2.5 7.0 5.0 7.5 6.5 30
  • The foams of Examples 41 and 47 were less hydrophilic than desired as can be seen by their high absorption rates. The foams of all the other Examples were satisfactory. The foams of Examples 43-46 were especially soft and uniform with distinct cosmetic odor.
  • EXAMPLES 48-57
  • These Examples illustrate the wide variety of combinations of isocyanate prepolymer, hydrophilic agent, adjuvant and wetting agent that may be used to form a hydrophilic foam composition in accordance with the present invention. The composition of the reactant compositions used are set forth in Table XIII.
  • The retained liquid, tightly held liquid, extractable materials and absorption rate for the foam compositions of these Examples are set forth in Table XIV. TABLE XIII
    REACTANT COMPOSITION EXAMPLE No.
    48 49 50 51 52 53 54 55 56 57
    I. PREPOLYMER
    Prepolymer A 20.00 20.00 10.00 10.00 20.00 15.00 10.00 10.00 10.00 10.00
    Prepolymer B 10.00 10.00 5.00 10.00 10.00 10.00 10.00
    II. HYDROPHILIC AGENT
    A 2.00 2.00 2.00 2.00 4.00 2.00 2.00 2.00 2.00 2.00
    D 1.00 1.00 1.00 2.00 2.00 2.00 2.00 2.00 2.00
    III. WATER 14.50 14.50 14.50 14.50 14.50 14.50 12.00 23.00 14.50
    Normal saline (0.85% NaCl) 14.50
    IV. ADJUVANT SYSTEM
    glycerin 5.00 5.00 5.00 15.00 10.00 9.00 13.00 10.00 10.00 10.00
    Honey 1.00 1.00 3.00 1.00 1.00 1.00 0.50 0.50 0.15
    propylene glycol 1.00 2.00
    V. WETTING AGENT
    Pluronic F-68 2.50 2.50 2.50 2.50 2.50 2.50 2.00 4.00 2.50 2.50
    Pluronic L-62 1.00
    Crodesta SL-40 1.00
    VI. OTHER
    FD&C Blue No. 1 Solution 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
    TABLE XIV
    EXAMPLE NO. 48 49 50 51 52 53 54 55 56 57
    RETAINED LIQUID
    Water 5.1 6.5 6.3 6.9 --- 11.1 12.2 8.5 11.6 12.2
    Tightly Held Water 2.6 4.1 4.6 5.0 --- 6.3 6.7 6.0 8.1 6.3
    % Extractable Material 25.0 17.0 24.0 29.3 --- 29.0 26.3 30.0 26.8 28.0
    ABSORPTION RATE 2.0 1.5 2.0 2.0 1.0 1.5 2.0 9.0 1.0 1.0
  • The foams of Examples 48, 50, 56 and 57 were acceptable. The foams of Examples 51 through 54 were more porous than desired, although the liquid retention and extractability were good. The amount of extractable material for the foam of Example 49 was somewhat low.

Claims (27)

1. A hydrophilic foam composition comprising the in situ reaction product of: a) an isocyanate-capped polyether prepolymer, b) a hydrophilic agent capable of absorbing water, c) an adjuvant comprising an alochol selected from the group consisting of water soluble monols, diols and polyhydric alcohols, d) a wetting agent, and e) water, said hydrophilic foam composition releasably carrying said adjuvant so that said foam composition is capable of absorbing an external liquid and tightly carrying said liquid in preference to at least a portion of said adjuvant so that said adjuvant is released in the presence of the external liquid.
2. A hydrophilic foam composition according to claim 1, wherein said prepolymer is selected from the group consisting of isocyanate-capped polyether polyols having an isocyanate equivalent weight of from about 0.5 meq/g to about 2.5 meq/g and mixtures thereof.
3. A hydrophilic foam composition according to claim 1 or claim 2, wherein said prepolymer is present in an amount of from about 20 wt. % to about 60 wt. % of the total reactant composition.
4. A hydrophilic foam composition according to any one of claims 1 to 3, wherein said hydrophilic agent is an absorptive polymer capable of absorbing water and having a fluid uptake of at least about 50 ml of water per gram of said polymer.
5. A hydrophilic foam composition according to any one of the preceding claims, wherein said hydrophilic agent is selected from the group consisting of starch grafted copolymers of acrylate salts, starch grafted copolymers of acrylamide salts, polyacrylate salts, and mixtures thereof.
6. A hydrophilic foam composition according to any one of the preceding claims, wherein said hydrophilic agent is present in an amount sufficient to provide a foam composition capable of absorbing at least about 3 times its weight of liquid.
7. A hydrophilic foam composition according to claim 6, wherein said foam composition is capable of tightly carrying at least about 3 times its weight of liquid.
8. A hydrophilic foam composition according to any one of the preceding claims, wherein said alcohol is a polyhydric alcohol having a molecular weight of less than about 1000.
9. A hydrophilic foam composition according to any one of claims 1 to 7, wherein said alcohol is selected from the group consisting of isopropyl alcohol, ethanol, propylene glycol, polyethylene glycol, polypropylene glycol, glycerine, 1,2,4-butanetriol, trimethylol-propane, sorbitol, pentaerythritol, and mixtures thereof.
10. A hydrophilic foam composition according to any one of the preceding claims, wherein said alcohol is present in an amount of from about 5% to about 30% by weight of the reactant composition.
11. A hydrophilic foam composition according to any one of the preceding claims, wherein said wetting agent is a non-ionic surfactant selected from the group consisting of block copolymers of ethylene oxide and propylene oxide, ethoxylated sorbitan fatty acid esters, glycerol esters, polyglycerol esters, silicone fluids and mixtures thereof.
12. A hydrophilic foam composition according to any one of the preceding claims, wherein said wetting agent is present in an amount of from about 1% to about 10% by weight of said reactant composition.
13. A hydrophilic foam composition according to any one of the preceding claims, wherein said prepolymer, said hydrophilic agent and said adjuvant are present in the reactant composition such that the ratio of prepolymer to hydrophilic agent is in the range of from about 20:1 to about 20:10 and the ratio of prepolymer to adjuvant is in the range of from about 20:2 to about 20:30.
14. A hydrophilic foam composition according to any one of the preceding claims, wherein said water is deionized water, distilled water or normal saline.
15. A hydrophilic foam composition according to claim 14, wherein said prepolymer is an isocyanate-capped polyether prepolymer having an isocyanate equivalent weight of about 1.6 meq/g and an equivalent weight per isocyanato group of about 625; said hydrophilic agent is starch-g-poly (2-propenamide-co-2-propenoic acid, mixed sodium and aluminum salt); said adjuvant comprises glycerine, and said wetting agent is a member selected from the group consisting of block copolymers of ethylene oxide and propylene oxide.
16. A wound dressing comprising a hydrophilic foam composition according to any one of the preceding claims.
17. A wound dressing comprising a hydrophilic foam composition comprising the in situ reaction product of
(a) an isocyanate-capped polyether prepolymer having an isocyanate equivalent weight of from about 0.5 meq/g to about 3 meq/g;
(b) a hydrophilic agent capable of absorbing water and having a fluid uptake of at least about 50 ml of water per gram of said agent, and wherein said hydrophilic agent comprises a hydrophilic material which is selected from the group consisting of starch grafted copolymers of acrylate salts, starch grafted copolymers of acrylamide salts, polyacrylate salts and mixtures thereof;
(c) an adjuvant comprising an alcohol selected from the group consisting of ethanol, isopropyl alcohol, propylene glycol, polyethylene glycol, polypropylene glycol, glycerine, 1,2,4-butanetriol, trimethylolpropane, pentaerythritol sorbitol, and mixtures thereof;
(d) a wetting agent comprising a non-ionic surfactant selected from the group consisting of block copolymers of ethylene oxide and propylene oxide, ethoxylated sorbitan fatty acid esters, glycerol esters, polyglycerol esters, silicone fluids and mixtures thereof; and
(e) water,
said hydrophilic foam composition releasably carrying said adjuvant so that said foam composition is capable of absorbing an external liquid and tightly carrying said liquid in preference to at least a portion of said adjuvant so that said adjuvant is released from said foam composition in the presence of the external liquid.
18. A wound dressing according to claim 17 wherein said water is deionized water, distilled water or normal saline.
19. A wound dressing according to any one of claims 16 to 18, wherein said hydrophilic agent comprises an additive selected from the group consisting of methylcellulose, guar gum, pectin, karaya gum, chitosan, agar, acacia powder, carrageenan, gelatin, and mixtures thereof.
20. A wound dressing according to any one of claims 16 to 19, wherein said adjuvant comprises at least one of a therapeutic agent, a medicament, and a cosmetic.
21. A wound dressing according to claim 20, wherein said adjuvant comprises a therapeutic agent selected from the group consisting of Collasol 2400, Crotein SPA, Crotein CAA, Cromoist HYA and hydrocortisone acetate.
22. A wound dressing according to claim 20, wherein said adjuvant comprises a cosmetic selected from the group consisting of European Collagen complex, Capture complex liposomes, bath oil, a hand lotion, a skin cream, Oil of Olay BF, Keri lotion, Vaseline herbal and aloe lotion, Ben Gay ointment and Retin-A cream.
23. A wound dressing according to claim 17, wherein said isocyanate-capped polyether prepolymer has an isocyanate equivalent weight of about 1.6 meq/g and an equivalent weight per isocyanato group of about 625; said hydrophilic agent is starch-g-poly (2-propenamide-­co-2-propenoic acid, mixed sodium and aluminum salt), said adjuvant comprises glycerin, and said wetting agent is selected from the group consisting of block copolymers of ethylene oxide and propylene oxide.
24. A wound dressing according to claim 23, wherein said prepolymer, said hydrophilic agent and said adjuvant are present in the reactant composition such that the ratio of prepolymer to hydrophilic agent is in the range of from about 20:1 to about 20:10 and the ratio of prepolymer to adjuvant is in the range of from about 20:2 to about 20:30.
25. A composite for use in a wound dressing comprising a substrate, a medically acceptable adhesive deposited on said substrate and a hydrophilic foam composition according to any one of claims 1 to 15 carried by said adhesive.
26. A method for making a composite for use in a wound dressing comprising:
providing a substrate,
applying a medically acceptable adhesive to said substrate,
applying a reactant composition to said adhesive, said reactant composition comprising an isocyanate-­capped polyether prepolymer, an hydrophilic agent capable of absorbing water, an adjuvant comprising an alcohol selected from the group consisting of water soluble monols, diols and polyhydric alcohols, a wetting agent and water, and
curing said reactant composition while it is in contact with said adhesive.
27. A method for making a composite for use in a wound dressing comprising:
providing a substrate,
applying a medically acceptable adhesive to said substrate,
applying a reactant composition to said adhesive, said reactant composition comprising
(a) an isocyanate-capped polyether prepolymer having an isocyanate equivalent weight of from about 0.5 meq/g to about 3 meq/g;
(b) a hydrophilic agent capable of absorbing water and having a fluid uptake of at least about 50 ml of water per gram of said agent, and wherein said hydrophilic agent comprises a hydrophilic material selected from the group consisting of starch grafted copolymers of acrylate salts, starch grafted copolymers of acrylamide salts, polyacrylate salts and mixtures thereof;
(c) an adjuvant comprising an alcohol selected from the group consisting of ethanol, isopropyl alcohol, propylene glycol, polyethylene glycol, polypropylene glycol, glycerin, 1,2,4-butanetriol, trimethylolpropane, pentaerythritol sorbitol, and mixtures thereof;
(d) a wetting agent comprising a non-ionic surfactant selected from the group consisting of block copolymers of ethylene oxide and propylene oxide, ethoxylated sorbitan fatty acid esters, glycerol esters, polyglycerol esters, silicone fluids and mixtures thereof; and
(e) water,
curing said reactant composition while it is in contact with said adhesive to form a foam composition that is unreleasably attached to said adhesive, said foam composition releasably carrying said adjuvant so that said foam composition is capable of absorbing an external liquid and tightly carrying said liquid in preference to at least a portion of said adjuvant so that said adjuvant is released from said foam composition in the presence of the external liquid.
EP89303064A 1988-03-29 1989-03-28 Hydrophilic foam compositions Expired - Lifetime EP0335669B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT89303064T ATE91074T1 (en) 1988-03-29 1989-03-28 HYDROPHILIC FOAM COMPOSITIONS.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US175036 1988-03-29
US07/175,036 US5064653A (en) 1988-03-29 1988-03-29 Hydrophilic foam compositions

Publications (3)

Publication Number Publication Date
EP0335669A2 true EP0335669A2 (en) 1989-10-04
EP0335669A3 EP0335669A3 (en) 1990-01-31
EP0335669B1 EP0335669B1 (en) 1993-06-30

Family

ID=22638574

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89303064A Expired - Lifetime EP0335669B1 (en) 1988-03-29 1989-03-28 Hydrophilic foam compositions

Country Status (9)

Country Link
US (1) US5064653A (en)
EP (1) EP0335669B1 (en)
JP (1) JPH07113067B2 (en)
KR (1) KR0131075B1 (en)
CN (1) CN1037523A (en)
AT (1) ATE91074T1 (en)
CA (1) CA1322072C (en)
DE (1) DE68907362T2 (en)
ES (1) ES2057111T3 (en)

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0424164A2 (en) * 1989-10-18 1991-04-24 Ferris Mfg., Corp. Process and apparatus for preparing a polymer-based foam
EP0426422A2 (en) * 1989-11-01 1991-05-08 Ndm Acquisition Corp. Hydrogel wound dressing product
EP0466552A2 (en) * 1990-06-29 1992-01-15 Technion Research & Development Foundation Ltd. Biomedical adhesive compositions
GB2253628A (en) * 1991-02-07 1992-09-16 Ultra Lab Ltd Wound dressings
DE4111098A1 (en) * 1991-04-05 1992-10-08 Beiersdorf Ag HYDROPHILIC SHEARS AND METHOD FOR THE PRODUCTION THEREOF
EP0541390A1 (en) * 1991-11-07 1993-05-12 JOHNSON & JOHNSON MEDICAL, INC. Wound dressing comprising polyurethane foam
EP0541391A1 (en) * 1991-11-07 1993-05-12 JOHNSON & JOHNSON MEDICAL, INC. Method of making polyurethane foam
WO1993019789A1 (en) * 1992-04-02 1993-10-14 Sebapharma Gmbh & Co. Wound dressing, wound plaster or carrier matrix
DE4308347A1 (en) * 1993-03-17 1994-09-29 Beiersdorf Ag Hydrophilic polyurethane foam gels, in particular for the treatment of deep wounds and process for their production
WO1996016099A1 (en) * 1994-11-22 1996-05-30 Imperial Chemical Industries Plc Process for making flexible foams
US5849850A (en) * 1994-11-22 1998-12-15 Imperial Chemical Industries Plc Process for making flexible foams
DE19804665A1 (en) * 1998-02-06 1999-08-12 Beiersdorf Ag Occlusion plaster used for correcting squints, especially in children
GB2336367A (en) * 1998-04-15 1999-10-20 Johnson & Johnson Medical Ltd Polyurethane foams for use in wound dressings
WO1999064081A1 (en) * 1998-06-08 1999-12-16 Ferris Corporation Analgesic and antinociceptive methods
AU720116B2 (en) * 1994-11-22 2000-05-25 Huntsman Ici Chemicals Llc Process for making flexible foams
WO2001060422A1 (en) * 2000-02-17 2001-08-23 3M Innovative Properties Company Foam/film composite medical articles
WO2001060423A1 (en) * 2000-02-17 2001-08-23 3M Innovative Properties Company Foam-on-film medical articles
US6326410B1 (en) 1992-11-04 2001-12-04 Johnson & Johnson Medical, Inc. Wound dressing comprising polyurethane foam
EP1268180A1 (en) * 2000-03-31 2003-01-02 Hydrophilix LLC Foam composite
US6509388B1 (en) 1999-02-11 2003-01-21 Johnson And Johnson Medical Limited Polyurethane foams for use in wound dressings
WO2004039421A1 (en) * 2002-10-29 2004-05-13 Biopol Co., Ltd. Polyurethane foam dressing for wound filler and method for man ufacturing thereof
WO2004062704A1 (en) * 2003-01-09 2004-07-29 Polyganics B.V. Biomedical foams
EP1494725A1 (en) * 2002-04-02 2005-01-12 H.H. Brown Shoe Technologies, Inc. Polyurethane foam products with controlled release of agents and additives
US6861067B2 (en) 1998-09-17 2005-03-01 Sherwood Services Ag Hydrogel wound dressing and the method of making and using the same
WO2007135069A1 (en) * 2006-05-22 2007-11-29 Basf Se Shoe soles displaying water absorbing properties
US7777091B2 (en) 2006-12-19 2010-08-17 Biopol Co., Ltd. Polyurethane foam dressing with improved moisturization
WO2011049522A1 (en) 2009-10-20 2011-04-28 Mölnlycke Health Care Ab Green article for use in wound treatment
EP2420214A1 (en) 2010-08-19 2012-02-22 Paul Hartmann AG Wound dressing comprising foam and salve basis for depression therapy
US8211255B2 (en) 2003-04-21 2012-07-03 Rynel Inc. Apparatus and methods for the attachment of materials to polyurethane foam, and articles made using them
WO2012150224A1 (en) * 2011-05-04 2012-11-08 Bayer Intellectual Property Gmbh Hydrophilic polyurethane foam with low volume swelling
EP2532325A1 (en) 2011-06-09 2012-12-12 Paul Hartmann AG Wound dressing comprising foam and cream base and swelling material for depression therapy
FR2978443A1 (en) * 2011-07-26 2013-02-01 Thales Sa Dielectric substrate material, useful for printed circuit and antennas, comprises polyurethane foam made of polyols comprising trimethylol-propane and isocyanate and additives such as catalyst based amine, surfactants and bubbling agent
WO2013095138A1 (en) 2011-12-23 2013-06-27 Polyganics B.V. Activated or biologically functionalised polymer network
US8980966B2 (en) 2009-08-29 2015-03-17 Bayer Materialscience Ag Hydrophilic aliphatic polyurethane foams
US9006163B2 (en) 2011-12-15 2015-04-14 Colgate-Palmolive Company Cleansing compositions with polyurethane-34
US9987364B2 (en) 2002-09-27 2018-06-05 Ferring B.V. Water-swellable polymers
US10105445B2 (en) 2006-07-05 2018-10-23 Ferring B.V. Hydrophilic polyurethane compositions
USD910159S1 (en) 2019-01-30 2021-02-09 Novia Products, Llc Scent dispenser
US10912855B2 (en) 2017-11-02 2021-02-09 Novia Products, Llc Scent dispenser/absorber and method using same
US11103026B2 (en) 2014-08-27 2021-08-31 Nike, Inc. Article of footwear with soil-shedding performance
US11207439B2 (en) 2018-05-01 2021-12-28 Novia Products, Llc Scent dispenser/absorber
US11445782B2 (en) 2014-08-27 2022-09-20 Nike, Inc. Articles of footwear, apparel, and sports equipment with soil-shedding properties
US11517071B2 (en) 2014-08-27 2022-12-06 Nike, Inc. Article of footwear with soil-shedding performance
US11540591B2 (en) 2016-03-02 2023-01-03 Nike, Inc. Hydrogel tie layer

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254301A (en) * 1988-03-29 1993-10-19 Ferris Mfg. Corp. Process for preparing a sheet of polymer-based foam
US5833665A (en) * 1990-06-14 1998-11-10 Integra Lifesciences I, Ltd. Polyurethane-biopolymer composite
US5562914A (en) * 1990-12-06 1996-10-08 Zeneca Inc. Impregnated porous granules and a polyurethane matrix held within the pores thereof and holding a liquid material for controlled release of liquid material and process therefor
DK0580778T3 (en) * 1991-04-19 2000-01-31 Lds Technologies Inc Convertible microemulsion formulations
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
AU670094B2 (en) * 1992-04-23 1996-07-04 Berlex Laboratories, Inc. Bioadhesive solid mineral oil emulsion
DE4308445A1 (en) * 1993-03-17 1994-09-22 Beiersdorf Ag Wound dressing based on hydrophilic polyurethane gel foams and process for their production
DE4233289A1 (en) * 1992-10-02 1994-04-07 Beiersdorf Ag Self adhesive polyurethane foam gel contg. water absorber - with non-aq. foaming agents, useful as plasters, wound dressings, etc., adheres to skin but not to wet wounds
JPH08504759A (en) * 1992-10-16 1996-05-21 アイビーエイエイチ・インコーポレーテッド Invertable microemulsion composition
DE4328190A1 (en) * 1993-08-23 1995-03-02 Beiersdorf Ag Wound care articles with selective absorbency
US5506277A (en) * 1994-06-30 1996-04-09 Kimberly-Clark Corporation Starch foams for absorbent articles
US5685834A (en) * 1994-07-29 1997-11-11 Barth; Alan H. Surgical dressing material
US5660854A (en) * 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6559353B1 (en) * 1995-01-19 2003-05-06 Christopher H. Sheridan Treated disposable articles for reducing skin breakdown
US5578317A (en) * 1995-03-31 1996-11-26 Mulder; Gerit D. Wound filler and method of manufacture
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
US5650450A (en) * 1996-01-25 1997-07-22 Foamex L.P. Hydrophilic urethane foam
US6349828B1 (en) 1997-02-06 2002-02-26 Ferris Pharmaceuticals Inc. Tamper evident packaging
US20050208114A1 (en) * 1998-03-24 2005-09-22 Petito George D Composition and method for healing tissues
US7691829B2 (en) * 1998-03-24 2010-04-06 Petito George D Composition and method for healing tissues
CN1081527C (en) * 1998-10-15 2002-03-27 张坤潢 Method for producing high-density polyurethane foamed material
US6198016B1 (en) 1998-12-01 2001-03-06 3M Innovative Properties Company Wet skin adhesive article
US6768040B1 (en) 2000-03-27 2004-07-27 Ferris Pharmaceuticals Inc. Wound dressing for treating injury to nasal passages
US6296607B1 (en) * 2000-10-20 2001-10-02 Praxis, Llc. In situ bulking device
US6399092B1 (en) * 2000-12-27 2002-06-04 Healthpoint, Ltd. Anhydrous, hydrophilic absorbent wound dressing (tube) with antimicrobials or other pharmaceutically active agents
US7078582B2 (en) 2001-01-17 2006-07-18 3M Innovative Properties Company Stretch removable adhesive articles and methods
US6894204B2 (en) 2001-05-02 2005-05-17 3M Innovative Properties Company Tapered stretch removable adhesive articles and methods
US7297395B2 (en) * 2002-07-30 2007-11-20 Kimberly-Clark Worldwide, Inc. Superabsorbent materials having low, controlled gel-bed friction angles and composites made from the same
US20040044320A1 (en) * 2002-08-27 2004-03-04 Kainth Arvinder Pal Singh Composites having controlled friction angles and cohesion values
US7846141B2 (en) 2002-09-03 2010-12-07 Bluesky Medical Group Incorporated Reduced pressure treatment system
GB0224986D0 (en) 2002-10-28 2002-12-04 Smith & Nephew Apparatus
US20040142020A1 (en) * 2003-01-16 2004-07-22 Healthpoint, Ltd. Anhydrous, hydrophilic absorbent wound dressing
US20050013987A1 (en) * 2003-07-16 2005-01-20 Roy Carr Foam-layered dressing, a method for making the same, a method for applying a dressing, a foam composition, and a foam layer composition produced by a process
US7022890B2 (en) * 2003-09-22 2006-04-04 Ferris Pharmaceuticals Wound dressing suitable for insertion in nasal passages
GB2410748A (en) * 2004-02-03 2005-08-10 Johnson & Johnson Medical Ltd Medicated polyurethane foams
US20060142529A1 (en) * 2004-02-06 2006-06-29 Verena Thiede Hydrophilic polyurethane polymers derived from a mdi-based isocyanate-terminated prepolymer
US10058642B2 (en) 2004-04-05 2018-08-28 Bluesky Medical Group Incorporated Reduced pressure treatment system
US7909805B2 (en) 2004-04-05 2011-03-22 Bluesky Medical Group Incorporated Flexible reduced pressure treatment appliance
US8062272B2 (en) 2004-05-21 2011-11-22 Bluesky Medical Group Incorporated Flexible reduced pressure treatment appliance
GB0409446D0 (en) 2004-04-28 2004-06-02 Smith & Nephew Apparatus
US7398883B2 (en) * 2005-05-23 2008-07-15 Tucker Kenneth H Blister kit and method of using same
CA2637173C (en) * 2006-01-31 2015-12-01 Tyco Healthcare Group Lp Super soft foams
US7485111B1 (en) * 2006-06-05 2009-02-03 Eugene Choi Medicated sleeve
MX2009001794A (en) * 2006-08-18 2009-07-22 Porex Corp Sintered polymeric materials and applications thereof.
GB0707758D0 (en) * 2007-04-21 2007-05-30 Smith & Nephew A foam material for medical use and method for producing same
KR100937816B1 (en) * 2007-06-21 2010-01-20 주식회사 원바이오젠 A Method for Manufacturing Hydrophilic Wound Dressing and the Hydrophilic Wound Dressing
US20090112141A1 (en) * 2007-10-31 2009-04-30 Derr Michael J Method and apparatus for providing a medical dressing
EP2987510B1 (en) 2007-11-21 2020-10-28 T.J. Smith & Nephew Limited Suction device and dressing
WO2009066106A1 (en) 2007-11-21 2009-05-28 Smith & Nephew Plc Wound dressing
US20130096518A1 (en) 2007-12-06 2013-04-18 Smith & Nephew Plc Wound filling apparatuses and methods
US11253399B2 (en) 2007-12-06 2022-02-22 Smith & Nephew Plc Wound filling apparatuses and methods
GB0723875D0 (en) 2007-12-06 2008-01-16 Smith & Nephew Wound management
GB0803564D0 (en) 2008-02-27 2008-04-02 Smith & Nephew Fluid collection
US8298200B2 (en) 2009-06-01 2012-10-30 Tyco Healthcare Group Lp System for providing continual drainage in negative pressure wound therapy
US8613834B2 (en) 2008-04-03 2013-12-24 Basf Se Paper coating or binding formulations and methods of making and using same
JP5264545B2 (en) * 2008-06-16 2013-08-14 テルモ株式会社 Liquid mixing method
DE102008031183A1 (en) 2008-07-03 2010-01-07 Paul Hartmann Ag wound dressing
EP2140888A1 (en) * 2008-07-04 2010-01-06 Bayer MaterialScience AG Layered compound, intended as wound dressing, containing a polyurethane foam layer, an absorbent layer and a covering layer
EP2143744A1 (en) 2008-07-09 2010-01-13 Bayer MaterialScience AG Hydrophilic aliphatic polyurethane foams
GB2476772B (en) * 2008-10-27 2013-09-25 Sessions Pharmaceuticals Inc Fluid extracting wound dressing
EP2336211A1 (en) 2009-12-12 2011-06-22 Bayer MaterialScience AG Hydrophilic aliphatic polyurethane foams
EP3520830B1 (en) 2009-12-22 2023-10-18 Smith & Nephew, Inc. Apparatuses for negative pressure wound therapy
DK2338529T3 (en) * 2009-12-24 2013-08-26 Hartmann Paul Ag Hydrogel matrix with improved adhesive properties
US8946315B2 (en) 2010-01-11 2015-02-03 Bayer Intellectual Property Gmbh Hydrophilic aliphatic polyurethane foams
US9061095B2 (en) 2010-04-27 2015-06-23 Smith & Nephew Plc Wound dressing and method of use
USRE48117E1 (en) 2010-05-07 2020-07-28 Smith & Nephew, Inc. Apparatuses and methods for negative pressure wound therapy
GB201011173D0 (en) 2010-07-02 2010-08-18 Smith & Nephew Provision of wound filler
BR112012030842A2 (en) 2010-07-02 2016-11-08 Indian Council Medical Res non-composite superabsorbents and composites, and method for producing non-composite superabsorbents and composites
JP2013535996A (en) * 2010-07-14 2013-09-19 バード・アクセス・システムズ,インコーポレーテッド Bandage device used with cannula or catheter
EP2632501B1 (en) 2010-10-27 2014-11-26 Bayer Intellectual Property GmbH Hydrophilic, aliphatic polyurethane foams
WO2012067620A1 (en) * 2010-11-18 2012-05-24 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of William Beaumont Army Spray foam splint
GB201020005D0 (en) 2010-11-25 2011-01-12 Smith & Nephew Composition 1-1
WO2012069794A1 (en) 2010-11-25 2012-05-31 Smith & Nephew Plc Composition i-ii and products and uses thereof
RU2582866C2 (en) 2010-12-22 2016-04-27 Смит Энд Нефью, Инк. Device and method of wound healing with negative pressure
US8461372B2 (en) * 2011-02-11 2013-06-11 Rao S. Bezwada Amino acid derivatives and absorbable polymers therefrom
US8901341B2 (en) 2011-02-11 2014-12-02 Bezwada Biomedical, Llc Amino acid derivatives and absorbable polymers therefrom
KR101257628B1 (en) 2011-03-24 2013-04-29 (주)아모레퍼시픽 Cosmetics comprising cosmetic composition impregnated in urethane foam
EP2532326B1 (en) 2011-06-09 2016-03-30 Paul Hartmann AG Wound dressing comprising non-woven and salve basis for negative pressure therapy
WO2012173812A1 (en) 2011-06-15 2012-12-20 Porex Corporation Sintered porous plastic liquid barrier media and applications thereof
US20150159066A1 (en) 2011-11-25 2015-06-11 Smith & Nephew Plc Composition, apparatus, kit and method and uses thereof
KR20130116182A (en) 2012-04-12 2013-10-23 (주)아모레퍼시픽 Foamed material of improvement in use
US9040093B2 (en) 2013-03-13 2015-05-26 Orthovita, Inc. Bone graft materials containing calcium phosphate and chitosan
US20160120706A1 (en) 2013-03-15 2016-05-05 Smith & Nephew Plc Wound dressing sealant and use thereof
GB2514592A (en) * 2013-05-30 2014-12-03 Medtrade Products Ltd Degradable haemostat composition
US9358256B2 (en) 2013-07-11 2016-06-07 Links Medical Products, Inc. Gap-patterned foam dressing and method of making same
WO2016181857A1 (en) 2015-05-08 2016-11-17 バンドー化学株式会社 Optical transparent adhesive sheet, method for producing optical transparent adhesive sheet, laminate and display device with touch panel
EP3328460A4 (en) * 2015-07-28 2019-03-27 NewMedical Technology, Inc. Systems and methods for making hydrophilic foams
EP3357985B1 (en) 2015-09-29 2023-02-01 Bando Chemical Industries, Ltd. Optically transparent pressure-sensitive adhesive sheet, laminate, process for producing laminate, and display device with touch panel
WO2017079169A1 (en) 2015-11-03 2017-05-11 Kimberly-Clark Worldwide, Inc. Paper tissue with high bulk and low lint
CN108292178B (en) 2015-11-26 2022-03-22 阪东化学株式会社 Optically transparent adhesive sheet, method for producing optically transparent adhesive sheet, laminate, and display device with touch panel
EP3412740B1 (en) * 2016-02-02 2023-07-12 Bando Chemical Industries, Ltd. Optical transparent adhesive sheet, optical transparent adhesive sheet production method, laminate, and touch panel-equipped display device
US10975190B2 (en) * 2016-07-21 2021-04-13 Bionanofoam Llc Bio-based and hydrophilic polyurethane prepolymer and foam made therefrom
JP7255059B2 (en) * 2016-12-29 2023-04-11 アルケア株式会社 Foams and foam compositions
USD830530S1 (en) 2017-03-17 2018-10-09 Novia Products, Llc Scent dispenser
AU2017441040B2 (en) 2017-11-29 2023-12-21 Kimberly-Clark Worldwide, Inc. Fibrous sheet with improved properties
CN108355162B (en) * 2018-05-14 2021-07-23 江西省科学院应用化学研究所 Medical dressing of antibiotic hydrophilic polyurethane foam
GB201811449D0 (en) 2018-07-12 2018-08-29 Smith & Nephew Apparatuses and methods for negative pressure wound therapy
GB2590316B (en) 2018-07-25 2022-06-01 Kimberly Clark Co Process for making three-dimensional foam-laid nonwovens
US11753514B2 (en) * 2018-08-24 2023-09-12 Cosmetic Foam Llc Modified formula for hydrophilic foam
GB202000574D0 (en) 2020-01-15 2020-02-26 Smith & Nephew Fluidic connectors for negative pressure wound therapy
TWI733503B (en) * 2020-06-22 2021-07-11 中鎮醫療產品科技股份有限公司 Polyurethane foam dressing and wound dressing products
CN113456877B (en) * 2021-07-09 2023-04-11 广西德之然生物科技有限公司 Organosilicon foam medical dressing and preparation method and application thereof
CN113912817A (en) * 2021-11-18 2022-01-11 中电保力(北京)科技有限公司 Water-swelling and water-blocking filling material and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049944A1 (en) * 1980-08-25 1982-04-21 Johnson & Johnson Absorbent products, process and compositions for immobilization of particulate absorbents
US4339550A (en) * 1981-01-26 1982-07-13 Carter-Wallace, Inc. Foam products
EP0171268A2 (en) * 1984-08-02 1986-02-12 Smith and Nephew Associated Companies p.l.c. Wound dressing
US4731391A (en) * 1986-07-18 1988-03-15 Kimberly-Clark Corporation Process of making a superabsorbent polyurethane foam

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2017596A (en) * 1934-05-11 1935-10-15 Otto J Kuhlke Flexible vehicle
NL177068B (en) * 1953-03-23 Bonfatti Lorenzo BEETROY DEVICE.
US2982394A (en) * 1955-07-13 1961-05-02 Ohio Commw Eng Co Soil conditioning package
US2900278A (en) * 1956-06-15 1959-08-18 Scott Paper Co Cellular product and method of making the same
US3419506A (en) * 1963-02-28 1968-12-31 Johnson & Johnson Pressurized composition for applying foamed dressings
US3419006A (en) * 1966-08-08 1968-12-31 Union Carbide Corp Novel dressing and use thereof
CH484220A (en) * 1967-11-13 1970-01-15 Elekal Manufacturing process of a flexible and hydrophilic polyurethane foam
US3961629A (en) * 1968-06-11 1976-06-08 American Cyanamid Company Using hydrophilic polyurethane laparotomy sponges
USRE32476E (en) * 1970-12-21 1987-08-18 Minnesota Mining And Manufacturing Company Consolidation of aggregate material
US3805532A (en) * 1970-12-21 1974-04-23 Minnesota Mining & Mfg Consolidation of aggregate material
US3889417A (en) * 1972-08-10 1975-06-17 Grace W R & Co Method for preparing horticultural foam structures
US3798836A (en) * 1972-12-04 1974-03-26 Dow Chemical Co A hydroponic bed for growing plants
US4137200A (en) * 1973-10-09 1979-01-30 W. R. Grace & Co. Crosslinked hydrophilic foams and method
US3973355A (en) * 1974-01-18 1976-08-10 Agritec Co. Self-contained hydrophilic plant growth matrix and method
PH13425A (en) * 1976-05-10 1980-04-23 Du Pont 2,3,8,12b-tetrahydro 1 h-3a,8-methano-dibenzo(3,4,6,7)cyclohepta(1,2-c)pyrrole derivatives pharmaceutical compositions containing same and method
US4069177A (en) * 1976-06-21 1978-01-17 Theodore Smith Water absorbing and urine stable step-wise grafted starch-polyacrylonitrile copolymers
DE2632545C2 (en) * 1976-07-20 1984-04-26 Collo Gmbh, 5303 Bornheim Cleaning body for personal care, household purposes and the like.
US4132839A (en) * 1976-10-12 1979-01-02 W. R. Grace & Co. Biodegradable hydrophilic foams and method
US4194998A (en) * 1976-12-06 1980-03-25 The United States Of America As Represented By The Secretary Of Agriculture Highly absorbent polyhydroxy polymer graft copolymers without saponification
LU76474A1 (en) * 1976-12-24 1978-07-10
US4156066A (en) * 1977-06-23 1979-05-22 Tyndale Plains - Hunter Ltd. Polyurethane polymers characterized by lactone groups and hydroxyl groups in the polymer backbone
NZ188633A (en) * 1977-10-18 1980-10-24 Unilever Ltd Absorbent material surface-treated with polyether
US4675009A (en) * 1977-11-07 1987-06-23 Lec Tec Corporation Drug dispensing device for transdermal delivery of medicaments
US4307717A (en) * 1977-11-07 1981-12-29 Lectec Corporation Sterile improved bandage containing a medicament
US4411262A (en) * 1978-04-21 1983-10-25 Bayer Aktiengesellschaft Constructional material
US4241537A (en) * 1979-05-10 1980-12-30 W. R. Grace & Co. Plant growth media utilizing polyurethane hydrogel
GB2070041B (en) * 1980-02-20 1983-06-22 Dunlop Ltd Polyether-urethane foams
US4363319A (en) * 1980-06-30 1982-12-14 Applied Medical Devices, Inc. Ready-to-use bandage incorporating a coagulant composition and method of preparing same
US4306551A (en) * 1980-07-28 1981-12-22 Lectec Corporation Sterile improved bandage and sealant
US4394930A (en) * 1981-03-27 1983-07-26 Johnson & Johnson Absorbent foam products
US4410571A (en) * 1980-08-25 1983-10-18 Johnson & Johnson Absorbent products, process and compositions for immobilization of particulate absorbents
US4341215A (en) * 1980-09-04 1982-07-27 Tampax Incorporated Absorbent device
US4517326A (en) * 1981-06-15 1985-05-14 Freeman Chemical Corporation Aqueous liquid filled polyurethane gels and method of making the same
US4415388A (en) * 1981-06-22 1983-11-15 Johnson & Johnson Method of making absorbent bearing products
GB2102012B (en) * 1981-07-02 1984-11-21 Peter Maurice Lock Wound dressing material
DE3128100C2 (en) * 1981-07-16 1986-05-22 Chemische Fabrik Stockhausen GmbH, 4150 Krefeld Absorbents for blood and serous body fluids
US4412036A (en) * 1981-08-05 1983-10-25 Grain Processing Corporation Composition for absorbent film and method and preparation
IL65438A (en) * 1982-04-06 1984-12-31 Israel Atomic Energy Comm Synthetic wound covering
US4497914A (en) * 1982-07-16 1985-02-05 C. R. Bard, Inc. Breathable ostomy gasket composition
JPS6045522B2 (en) * 1982-12-08 1985-10-09 憲司 中村 cosmetic tools
US4579578A (en) * 1983-06-04 1986-04-01 Chemical Discoveries S.A. Plant growing media
SE460017B (en) * 1984-03-14 1989-09-04 Landstingens Inkopscentral BACTERY-ADDRESSING COMPOSITION IN WATER-SOLUBLE FORM
US4671267A (en) * 1984-05-30 1987-06-09 Edward I. Stout Gel-based therapy member and method
US4614787A (en) * 1984-11-13 1986-09-30 Thermedics, Inc. Drug dispensing wound dressing
US4668564A (en) * 1985-12-26 1987-05-26 Spenco Medical Corporation Hydrogel materials for hot and cold therapy and method for forming same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049944A1 (en) * 1980-08-25 1982-04-21 Johnson & Johnson Absorbent products, process and compositions for immobilization of particulate absorbents
US4339550A (en) * 1981-01-26 1982-07-13 Carter-Wallace, Inc. Foam products
EP0171268A2 (en) * 1984-08-02 1986-02-12 Smith and Nephew Associated Companies p.l.c. Wound dressing
US4731391A (en) * 1986-07-18 1988-03-15 Kimberly-Clark Corporation Process of making a superabsorbent polyurethane foam

Cited By (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0424164A2 (en) * 1989-10-18 1991-04-24 Ferris Mfg., Corp. Process and apparatus for preparing a polymer-based foam
EP0424164A3 (en) * 1989-10-18 1992-04-29 Ferris Mfg., Corp. Process and apparatus for preparing a polymer-based foam
EP0426422A2 (en) * 1989-11-01 1991-05-08 Ndm Acquisition Corp. Hydrogel wound dressing product
EP0426422A3 (en) * 1989-11-01 1991-09-11 Ndm Acquisition Corp. Hydrogel wound dressing product
EP0466552A2 (en) * 1990-06-29 1992-01-15 Technion Research & Development Foundation Ltd. Biomedical adhesive compositions
EP0466552A3 (en) * 1990-06-29 1992-05-06 Technion Research & Development Foundation Ltd. Biomedical adhesive compositions
GB2253628B (en) * 1991-02-07 1995-06-21 Ultra Lab Ltd Wound dressings
US5914125A (en) * 1991-02-07 1999-06-22 Ultra Laboratories Limited Wound dressing
GB2253628A (en) * 1991-02-07 1992-09-16 Ultra Lab Ltd Wound dressings
DE4111098A1 (en) * 1991-04-05 1992-10-08 Beiersdorf Ag HYDROPHILIC SHEARS AND METHOD FOR THE PRODUCTION THEREOF
EP0541390A1 (en) * 1991-11-07 1993-05-12 JOHNSON & JOHNSON MEDICAL, INC. Wound dressing comprising polyurethane foam
EP0541391A1 (en) * 1991-11-07 1993-05-12 JOHNSON & JOHNSON MEDICAL, INC. Method of making polyurethane foam
SG89233A1 (en) * 1991-11-07 2002-06-18 Johnson & Johnson Medical Method of making polyurethane foam
US5571529A (en) * 1991-11-07 1996-11-05 Johnson & Johnson Medical, Inc. Method of making polyurethane foam
WO1993019789A1 (en) * 1992-04-02 1993-10-14 Sebapharma Gmbh & Co. Wound dressing, wound plaster or carrier matrix
US6326410B1 (en) 1992-11-04 2001-12-04 Johnson & Johnson Medical, Inc. Wound dressing comprising polyurethane foam
DE4308347A1 (en) * 1993-03-17 1994-09-29 Beiersdorf Ag Hydrophilic polyurethane foam gels, in particular for the treatment of deep wounds and process for their production
EP0894814A1 (en) * 1994-11-22 1999-02-03 Imperial Chemical Industries Plc Process for making flexible foams
US5849850A (en) * 1994-11-22 1998-12-15 Imperial Chemical Industries Plc Process for making flexible foams
AU720116B2 (en) * 1994-11-22 2000-05-25 Huntsman Ici Chemicals Llc Process for making flexible foams
WO1996016099A1 (en) * 1994-11-22 1996-05-30 Imperial Chemical Industries Plc Process for making flexible foams
DE19804665A1 (en) * 1998-02-06 1999-08-12 Beiersdorf Ag Occlusion plaster used for correcting squints, especially in children
US6890551B2 (en) 1998-02-06 2005-05-10 Beiersdorf Ag Light occlusive patch
DE19804665B4 (en) * 1998-02-06 2004-09-23 Beiersdorf Ag Opaque eye patch
WO1999052569A1 (en) * 1998-04-15 1999-10-21 Johnson & Johnson Medical Limited Polyurethane foams for use in wound dressings
GB2336367A (en) * 1998-04-15 1999-10-20 Johnson & Johnson Medical Ltd Polyurethane foams for use in wound dressings
GB2336367B (en) * 1998-04-15 2002-03-27 Johnson & Johnson Medical Ltd Polyurethane foams for use in wound dressings
US7875294B2 (en) 1998-06-08 2011-01-25 Sessions Pharmaceuticals Inc. Method of attenuating bruise formation
US6447802B2 (en) 1998-06-08 2002-09-10 Ferris Corporation Analgesic and antinociceptive methods
US6451301B1 (en) 1998-06-08 2002-09-17 Ferris Corporation Analgesic and antinociceptive methods
US8486454B2 (en) 1998-06-08 2013-07-16 Sessions Pharmaceuticals Inc. Method of attenuating neurogenic pain
US7078056B2 (en) 1998-06-08 2006-07-18 Ferris Pharmaceuticals Inc. Method of attenuating bruise formation
US8101206B2 (en) 1998-06-08 2012-01-24 Sessions Pharmaceuticals Inc. Method of attenuating swelling or inflammation
US7078055B2 (en) 1998-06-08 2006-07-18 Ferris Pharmaceuticals Inc. Method of attenuating swelling or inflammation
WO1999064081A1 (en) * 1998-06-08 1999-12-16 Ferris Corporation Analgesic and antinociceptive methods
US7709005B2 (en) 1998-06-08 2010-05-04 Sessions Pharmaceuticals Inc. Method of attenuating neurogenic swelling or neurogenic inflammation
US7625585B2 (en) 1998-06-08 2009-12-01 Sessions Pharmaceuticals Inc. Method of attenuating neurogenic bruise formation
US6861067B2 (en) 1998-09-17 2005-03-01 Sherwood Services Ag Hydrogel wound dressing and the method of making and using the same
US6509388B1 (en) 1999-02-11 2003-01-21 Johnson And Johnson Medical Limited Polyurethane foams for use in wound dressings
WO2001060423A1 (en) * 2000-02-17 2001-08-23 3M Innovative Properties Company Foam-on-film medical articles
EP1842563A1 (en) * 2000-02-17 2007-10-10 3M Innovative Properties Company Foam/film composite medical articles
WO2001060422A1 (en) * 2000-02-17 2001-08-23 3M Innovative Properties Company Foam/film composite medical articles
US7048966B2 (en) 2000-03-31 2006-05-23 Hydrophilix, Llc Foam composite
EP1268180A1 (en) * 2000-03-31 2003-01-02 Hydrophilix LLC Foam composite
US6991848B2 (en) 2000-03-31 2006-01-31 Hydrophilix Llc Foam composite
EP1268180A4 (en) * 2000-03-31 2005-01-19 Hydrophilix Llc Foam composite
EP1494725A1 (en) * 2002-04-02 2005-01-12 H.H. Brown Shoe Technologies, Inc. Polyurethane foam products with controlled release of agents and additives
EP1494725A4 (en) * 2002-04-02 2006-08-16 Hh Brown Shoe Tech Inc Polyurethane foam products with controlled release of agents and additives
US9987364B2 (en) 2002-09-27 2018-06-05 Ferring B.V. Water-swellable polymers
US7777090B2 (en) 2002-10-29 2010-08-17 Biopol Co., Ltd. Polyurethane foam dressing for wound filler and method for manufacturing thereof
EP1562648A1 (en) * 2002-10-29 2005-08-17 Biopol Co., Ltd. Polyurethane foam dressing for wound filler and method for manufacturing thereof
EP1562648A4 (en) * 2002-10-29 2008-04-02 Biopol Co Ltd Polyurethane foam dressing for wound filler and method for manufacturing thereof
WO2004039421A1 (en) * 2002-10-29 2004-05-13 Biopol Co., Ltd. Polyurethane foam dressing for wound filler and method for man ufacturing thereof
US11147898B2 (en) 2003-01-09 2021-10-19 Stryker European Operations Holdings Llc Biomedical foams
CN101816801B (en) * 2003-01-09 2012-11-14 聚合物器官股份有限公司 Biomedical foams, preparation thereof and application
US9610377B2 (en) 2003-01-09 2017-04-04 Stryker European Holdings I, Llc Biomedical foams
US11911524B2 (en) 2003-01-09 2024-02-27 Stryker European Operations Holdings Llc Biomedical foams
WO2004062704A1 (en) * 2003-01-09 2004-07-29 Polyganics B.V. Biomedical foams
US10507260B2 (en) 2003-01-09 2019-12-17 Stryker European Holdings I, Llc Biomedical foams
US8211255B2 (en) 2003-04-21 2012-07-03 Rynel Inc. Apparatus and methods for the attachment of materials to polyurethane foam, and articles made using them
WO2007135069A1 (en) * 2006-05-22 2007-11-29 Basf Se Shoe soles displaying water absorbing properties
US10105445B2 (en) 2006-07-05 2018-10-23 Ferring B.V. Hydrophilic polyurethane compositions
US7777091B2 (en) 2006-12-19 2010-08-17 Biopol Co., Ltd. Polyurethane foam dressing with improved moisturization
US8980966B2 (en) 2009-08-29 2015-03-17 Bayer Materialscience Ag Hydrophilic aliphatic polyurethane foams
WO2011049522A1 (en) 2009-10-20 2011-04-28 Mölnlycke Health Care Ab Green article for use in wound treatment
WO2012022484A1 (en) 2010-08-19 2012-02-23 Paul Hartmann Ag Wound dressing containing foam material and an ointment base for negative pressure therapy
EP2702969A1 (en) 2010-08-19 2014-03-05 Paul Hartmann AG Wound dressing; containing foam and ointment base for vacuum therapy
EP2420214A1 (en) 2010-08-19 2012-02-22 Paul Hartmann AG Wound dressing comprising foam and salve basis for depression therapy
US9364577B2 (en) 2011-05-04 2016-06-14 Covestro Deutschland Ag Hydrophilic polyurethane foam with low volume swelling
WO2012150224A1 (en) * 2011-05-04 2012-11-08 Bayer Intellectual Property Gmbh Hydrophilic polyurethane foam with low volume swelling
WO2012167942A1 (en) 2011-06-09 2012-12-13 Paul Hartmann Ag Wound dressing containing foam material and an ointment base and a swelling agent for negative pressure therapy
EP2532325A1 (en) 2011-06-09 2012-12-12 Paul Hartmann AG Wound dressing comprising foam and cream base and swelling material for depression therapy
FR2978443A1 (en) * 2011-07-26 2013-02-01 Thales Sa Dielectric substrate material, useful for printed circuit and antennas, comprises polyurethane foam made of polyols comprising trimethylol-propane and isocyanate and additives such as catalyst based amine, surfactants and bubbling agent
US9006163B2 (en) 2011-12-15 2015-04-14 Colgate-Palmolive Company Cleansing compositions with polyurethane-34
WO2013095138A1 (en) 2011-12-23 2013-06-27 Polyganics B.V. Activated or biologically functionalised polymer network
US11103026B2 (en) 2014-08-27 2021-08-31 Nike, Inc. Article of footwear with soil-shedding performance
US11178933B2 (en) 2014-08-27 2021-11-23 Nike, Inc. Article of footwear with soil-shedding performance
US11445782B2 (en) 2014-08-27 2022-09-20 Nike, Inc. Articles of footwear, apparel, and sports equipment with soil-shedding properties
US11517071B2 (en) 2014-08-27 2022-12-06 Nike, Inc. Article of footwear with soil-shedding performance
US11540591B2 (en) 2016-03-02 2023-01-03 Nike, Inc. Hydrogel tie layer
US10912855B2 (en) 2017-11-02 2021-02-09 Novia Products, Llc Scent dispenser/absorber and method using same
US11207439B2 (en) 2018-05-01 2021-12-28 Novia Products, Llc Scent dispenser/absorber
USD910159S1 (en) 2019-01-30 2021-02-09 Novia Products, Llc Scent dispenser

Also Published As

Publication number Publication date
CN1037523A (en) 1989-11-29
KR0131075B1 (en) 1998-04-17
ATE91074T1 (en) 1993-07-15
ES2057111T3 (en) 1994-10-16
JPH0243231A (en) 1990-02-13
EP0335669A3 (en) 1990-01-31
US5064653A (en) 1991-11-12
JPH07113067B2 (en) 1995-12-06
CA1322072C (en) 1993-09-07
DE68907362D1 (en) 1993-08-05
KR890014642A (en) 1989-10-25
DE68907362T2 (en) 1993-10-14
EP0335669B1 (en) 1993-06-30

Similar Documents

Publication Publication Date Title
EP0335669B1 (en) Hydrophilic foam compositions
US5065752A (en) Hydrophilic foam compositions
US5254301A (en) Process for preparing a sheet of polymer-based foam
US20220331478A1 (en) Systems and Methods for Making Hydrophilic Foams
JP3345059B2 (en) Production method of polyurethane foam
AU2003208303B2 (en) A wound care device
CA2082365C (en) Wound dressing comprising polyurethane foam
US6326410B1 (en) Wound dressing comprising polyurethane foam
AU2003243262A1 (en) Hydrophilic foam compositions having antimicrobial properties
AU756214B2 (en) Polyurethane foams for use in wound dressings
CA2027894C (en) Process for preparing a sheet of polymer-based foam
AU624808B2 (en) Hydrophilic foam compositions
EP4338762A1 (en) Process of producing a highly absorbent hydrogel composition for medical purposes, in particular for wound treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19900404

17Q First examination report despatched

Effective date: 19911028

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 91074

Country of ref document: AT

Date of ref document: 19930715

Kind code of ref document: T

ITF It: translation for a ep patent filed
REF Corresponds to:

Ref document number: 68907362

Country of ref document: DE

Date of ref document: 19930805

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3008568

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

EPTA Lu: last paid annual fee
26N No opposition filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2057111

Country of ref document: ES

Kind code of ref document: T3

EAL Se: european patent in force in sweden

Ref document number: 89303064.3

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20080313

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20080306

Year of fee payment: 20

Ref country code: LU

Payment date: 20080328

Year of fee payment: 20

Ref country code: NL

Payment date: 20080203

Year of fee payment: 20

Ref country code: IT

Payment date: 20080327

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20080313

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20080418

Year of fee payment: 20

Ref country code: DE

Payment date: 20080407

Year of fee payment: 20

Ref country code: FR

Payment date: 20080311

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20080402

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20080215

Year of fee payment: 20

Ref country code: BE

Payment date: 20080916

Year of fee payment: 20

BE20 Be: patent expired

Owner name: *FERRIS MFG. CORP.

Effective date: 20090328

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20090327

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20090330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20090328

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20090328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20090327

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20090330